uu.seUppsala University Publications
Change search
Refine search result
23456 201 - 250 of 295
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 201. Qvortrup, C.
    et al.
    Cvancarova, M.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Pfeiffer, P.
    Sorbye, H.
    Age dependent increase in median and long-term survival in 29 628 metastatic colorectal cancer (mcrc) scandinavian patients during the past two decades2012In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 23, no S9, p. 188-188Article in journal (Other academic)
  • 202. Racadot, S.
    et al.
    Hammel, P.
    Chibaudel, B.
    Goldstein, D.
    Spry, N.
    Van Laethem, J.
    Van Houtte, P.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Gubanski, M.
    Huguet, F.
    Dummy Run in the Phase III LAP07 Pancreatic Cancer Trial: First Evaluation of Quality of Radiation Therapy Planning2012In: International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, E-ISSN 1879-355X, Vol. 84, no 3, p. S322-S322Article in journal (Other academic)
  • 203.
    Radu, Calin
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Norrlid, Ola
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Braendengen, Morten
    Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Oncology, Oslo University Hospital, Oslo, Norway.
    Hansson, Karl
    Department of Diagnostic Radiology, Karolinska University Hospital, Solna, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
    Isacsson, Ulf
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients2013In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 52, no 3, p. 528-537Article in journal (Refereed)
    Abstract [en]

    Background and Purpose.

    Few studies have explored the potential clinical advantages of dose escalation and integrated boosts for patients with non-resectable locally advanced rectal cancer. The possibility of escalating dose to non-resectable regions in these patients was the aim of this study.

    Patients and methods.

    Seven patients with locally very advanced rectal tumours (sacrum overgrowth or growth into pelvic side walls) were evaluated. Intensity modulated photon and pencil beam scanning proton plans with simultaneously integrated boosts (45 Gy to elective lymph nodes, 50 Gy to tumour and 62.5 Gy to boost area in 25 fractions) were compared.

    Results.

    Target coverage was achieved with both photon and proton plans. Estimated risks of acute side effects put the two patients with the largest tumours at unacceptable risk for intestinal toxicity, regardless of modality. The remaining five patients had beneficial sparing of dose to the small intestine with protons.

    Conclusions.

    Adding boost to areas where rectal tumours infiltrate adjacent non-resectable organs is an attractive option which appears possible using both photon and proton irradiation. Proton plans reduced dose to organs at risk. Integrated peripheral boosts should be considered more frequently in these very advanced tumours.

  • 204.
    Rasmussen, Markus
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Sundström, Magnus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular and Morphological Pathology.
    Kultima, Hanna Göransson
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Botling, Johan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular and Morphological Pathology.
    Micke, Patrick
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular and Morphological Pathology.
    Birgisson, Helgi
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Colorectal Surgery.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Isaksson, Anders
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity2011In: Genome Biology, ISSN 1465-6906, E-ISSN 1474-760X, Vol. 12, no 10, p. R108-Article in journal (Refereed)
    Abstract [en]

    We describe a bioinformatic tool, Tumor Aberration Prediction Suite (TAPS), for the identification of allele-specific copy numbers in tumor samples using data from Affymetrix SNP arrays. It includes detailed visualization of genomic segment characteristics and iterative pattern recognition for copy number identification, and does not require patient-matched normal samples. TAPS can be used to identify chromosomal aberrations with high sensitivity even when the proportion of tumor cells is as low as 30%. Analysis of cancer samples indicates that TAPS is well suited to investigate samples with aneuploidy and tumor heterogeneity, which is commonly found in many types of solid tumors.

  • 205.
    Ring, Lena
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
    Kettis Lindblad, Åsa
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
    Bendtsen, P
    Viklund, E
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
    Jansson, R
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Oncology.
    Feasibility and validity of a computer administered version of SEIQoL-DW2006In: Quality of Life Research, ISSN 0962-9343, E-ISSN 1573-2649, Vol. 15, no 7, p. 1173-1177Article in journal (Refereed)
    Abstract [en]

    Computer administrered QoL instruments are increasingly used to assess outcomes. Our aim was to assess the feasibility and validity of an electronic version of the SEIQoL-DW. Pharmacy students (n = 40; mean age 25; 92% women) were administrated both the touch screen and the paper-and-pen versions in a cross-over study. The majority of the students (65 %) preferred the computer version, while almost a third (27%) preferred the paper and pen version. There was no overall order effect and the SEOQoL-DW index mean scores differed with 1.2 between the two versions. Those respondents completing the computer version first had higher scores than those completing the computer version second. The ICC comparing the formats was 0.77 (CI: 0.57-0.88) and the limits of agreement method showed that 85% of the observations were within +/- 1-10 units. Most students (82%) judged their QoL as being equivalent to their SEIQoL-DW score. The computer version of the SEIQoL-DW seems to be feasible and acceptable and seems to be valid alternative to the paper and pen version. However, further validation studies in larger patient populations are needed.

  • 206.
    Ring, Lena
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics.
    Wettergren, Lena
    Fagerlind, Hanna
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Lindberg, Mathilde Hedlund
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics.
    Kettis, Åsa
    Uppsala University, University Administration, Planning Division.
    QOL assessments in clinical practice: usefulness of ERORTC-QLQC-30 and the SEIOQL2014In: Quality of Life Research, ISSN 0962-9343, E-ISSN 1573-2649, Vol. 23, p. 104-104Article in journal (Other academic)
  • 207.
    Robles-Zurita, Jose
    et al.
    Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland.
    Boyd, Kathleen A.
    Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland.
    Briggs, Andrew H.
    Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland.
    Iveson, Timothy
    Southampton Univ Hosp NHS Fdn Trust, Southampton, Hants, England.
    Kerr, Rachel S.
    Univ Oxford, Dept Oncol, Oxford, England.
    Saunders, Mark P.
    Christie Hosp, Manchester, Lancs, England.
    Cassidy, Jim
    Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland.
    Hollander, Niels Henrik
    Zealand Univ Hosp, Dept Oncol & Palliat Care, Radmandsengen 5, DK-4700 Naestved, Denmark.
    Tabernero, Josep
    Univ Autonoma Barcelona, CIBERONC, Vall dHebron Univ Hosp, Barcelona, Spain;Univ Autonoma Barcelona, CIBERONC, Inst Oncol VHIO, Barcelona, Spain.
    Segelov, Eva
    Australasian Gastrointestinal Trials Grp AGITG, Melbourne, Vic, Australia;Monash Univ, Melbourne, Vic, Australia;Monash Hlth, Melbourne, Vic, Australia.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Harkin, Andrea
    Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland.
    Allan, Karen
    Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland.
    McQueen, John
    Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland.
    Pearson, Sarah
    Univ Oxford, OCTO, Dept Oncol, Oxford, England.
    Waterston, Ashita
    Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.
    Medley, Louise
    Royal United Hosp, Bath, Avon, England.
    Wilson, Charles
    Addenbrookes Hosp, Cambridge, England.
    Ellis, Richard
    Royal Cornwall Hosp NHS Trust, Truro, Cornwall, England.
    Essapen, Sharadah
    Royal Surrey Cty Hosp NHS Fdn Trust, St Lukes Canc Ctr, Guildford, Surrey, England.
    Dhadda, Amandeep S.
    Castle Hill Hosp, Kingston Upon Hull, N Humberside, England.
    Hughes, Rob
    Mt Vernon Canc Ctr, Northwood, Middx, England.
    Falk, Stephen
    Bristol Canc Inst, Bristol, Avon, England.
    Raouf, Sherif
    Barking Havering & Redbridge Univ Hosp NHS Trust, Barking, England.
    Rees, Charlotte
    Southampton Univ Hosp NHS Fdn Trust, Southampton, Hants, England.
    Olesen, Rene K.
    Zealand Univ Hosp, Dept Oncol & Palliat Care, Radmandsengen 5, DK-4700 Naestved, Denmark.
    Propper, David
    Queen Mary Univ London, Barts Canc Inst, London, England.
    Bridgewater, John
    UCL, London, England.
    Azzabi, Ashraf
    Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England.
    Farrugia, David
    Cheltenham Gen Hosp, Gloucestershire Oncol Ctr, Cheltenham, Glos, England.
    Webb, Andrew
    Brighton & Sussex Univ Hosp Trust, Brighton, E Sussex, England.
    Cunningham, David
    Royal Marsden, London, England.
    Hickish, Tamas
    Bournemouth Univ, Poole Hosp, Bournemouth, Dorset, England.
    Weaver, Andrew
    Oxford Univ Hosp Fdn Trust, Churchill Hosp, Oxford, England.
    Gollins, Simon
    North Wales Canc Treatment Ctr, Rhyl, Wales.
    Wasan, Harpreet S.
    Imperial Coll London, Hammersmith Hosp, London, England.
    Paul, James
    Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland.
    SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer2018In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 119, no 11, p. 1332-1338Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer.

    METHODS: In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken.

    RESULTS: The 3M arm is less costly (-4881; pound 95% CI: -6269; pound -3492) pound and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3M had lower QALYs than 6M (not statistically significant).

    CONCLUSIONS: Overall, 3M dominates 6M with no significant detrimental impact on QALYs. The results provide the economic case that a 3M treatment strategy should be considered a new standard of care.

  • 208. Rollven, Erik
    et al.
    Holm, Torbjorn
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Lorinc, Esther
    Blomqvist, Lennart
    Potentials of high resolution magnetic resonance imaging versus computed tomography for preoperative local staging of colon cancer2013In: Acta Radiologica, ISSN 0284-1851, E-ISSN 1600-0455, Vol. 54, no 7, p. 722-730Article in journal (Refereed)
    Abstract [en]

    Background: Preoperative identification of locally advanced colon cancer is of importance in order toproperly plan treatment. Purpose: To study high resolution T2-weighted magnetic resonance imaging (MRI) versus computed tomography (CT) for preoperative staging of colon cancer with surgery and histopathology as reference standard. Material and Methods: Twenty-eight patients with a total of 29 tumors were included. Patients were examined on a 1.5 T MR unit using a phased array body coil. T2 turbo spin-echo high resolution sequences were obtained in a coronal, transverse, and perpendicular plane to the long axis of the colon at the site of the tumor. Contrast-enhanced CT was performed using a protocol for metastasis staging. The examinations were independently evaluated by two gastrointestinal radiologists using criteria adapted to imaging for prediction of T-stage, N-stage, and extramural venous invasion. Based on the T-stage, tumors were divided in to locally advanced (T3cd-T4) and not locally advanced (T1-T3ab). Surgical and histopathological findings served as reference standard. Results: Using MRI, T-stage, N-stage, and extramural venous invasion were correctly predicted for each observer in 90% and 93%, 72% and 69%, and 82% and 78% of cases, respectively. With CT the corresponding results were 79% and 76%, 72% and 72%, 78% and 67%. For MRI inter-observer agreements (Kappa statistics) were 0.79, 0.10, and 0.76. For CT the corresponding results were 0.64, 0.66, and 0.22. Conclusion: Patients with locally advanced colon cancer, defined as tumor stage T3cd-T4, can be identified by both high resolution MRI and CT, even when CT is performed with a metastasis staging protocol. MRI may have an advantage, due to its high soft tissue discrimination, to identify certain prognostic factors such as T-stage and extramural venous invasion.

  • 209. Rosmarin, Dan
    et al.
    Palles, Claire
    Church, David
    Domingo, Enric
    Jones, Angela
    Johnstone, Elaine
    Wang, Haitao
    Love, Sharon
    Julier, Patrick
    Scudder, Claire
    Nicholson, George
    Gonzalez-Neira, Anna
    Martin, Miguel
    Sargent, Daniel
    Green, Erin
    McLeod, Howard
    Zanger, Ulrich M
    Schwab, Matthias
    Braun, Michael
    Seymour, Matthew
    Thompson, Lindsay
    Lacas, Benjamin
    Boige, Valérie
    Ribelles, Nuria
    Afzal, Shoaib
    Enghusen, Henrik
    Jensen, Søren Astrup
    Etienne-Grimaldi, Marie-Christine
    Milano, Gérard
    Wadelius, Mia
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical pharmacogenomics and osteoporosis.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science.
    Garmo, Hans
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center.
    Gusella, Milena
    Lecomte, Thierry
    Laurent-Puig, Pierre
    Martinez-Balibrea, Eva
    Sharma, Rohini
    Garcia-Foncillas, Jesus
    Kleibl, Zdenek
    Morel, Alain
    Pignon, Jean-Pierre
    Midgley, Rachel
    Kerr, David
    Tomlinson, Ian
    Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis2014In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 10, p. 1031-1039Article in journal (Refereed)
    Abstract [en]

    PURPOSE: Fluourouracil (FU) is a mainstay of chemotherapy, although toxicities are common. Genetic biomarkers have been used to predict these adverse events, but their utility is uncertain.

    PATIENTS AND METHODS: We tested candidate polymorphisms identified from a systematic literature search for associations with capecitabine toxicity in 927 patients with colorectal cancer in the Quick and Simple and Reliable trial (QUASAR2). We then performed meta-analysis of QUASAR2 and 16 published studies (n = 4,855 patients) to examine the polymorphisms in various FU monotherapy and combination therapy regimens.

    RESULTS: Global capecitabine toxicity (grades 0/1/2 v grades 3/4/5) was associated with the rare, functional DPYD alleles 2846T>A and *2A (combined odds ratio, 5.51; P = .0013) and with the common TYMS polymorphisms 5'VNTR2R/3R and 3'UTR 6bp ins-del (combined odds ratio, 1.31; P = 9.4 × 10(-6)). There was weaker evidence that these polymorphisms predict toxicity from bolus and infusional FU monotherapy. No good evidence of association with toxicity was found for the remaining polymorphisms, including several currently included in predictive kits. No polymorphisms were associated with toxicity in combination regimens.

    CONCLUSION: A panel of genetic biomarkers for capecitabine monotherapy toxicity would currently comprise only the four DPYD and TYMS variants above. We estimate this test could provide 26% sensitivity, 86% specificity, and 49% positive predictive value-better than most available commercial kits, but suboptimal for clinical use. The test panel might be extended to include additional, rare DPYD variants functionally equivalent to *2A and 2846A, though insufficient evidence supports its use in bolus, infusional, or combination FU. There remains a need to identify further markers of FU toxicity for all regimens.

  • 210.
    Sahlberg, Sara Haggblad
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Biomedical Radiation Sciences.
    Gustafsson, Ann-Sofie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Biomedical Radiation Sciences.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Stenerlöw, Bo
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Biomedical Radiation Sciences.
    Radiation response in colorectal cancer cells2012In: International Journal of Molecular Medicine, ISSN 1107-3756, E-ISSN 1791-244X, Vol. 30, no S1, p. S7-S7Article in journal (Other academic)
  • 211. Salazar, Ramon
    et al.
    Capdevila, Jaume
    Rosenberg, Robert
    de Waard, Jan Willem
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Bibeau, Frederic
    Klaase, Joost
    Van der Hoeven, Jacobus J. M.
    Midgley, Rachel A.
    Chang, George J.
    Bachleitner-Hofmann, Thomas
    Asano, Michio
    Ziebermayr, Reinhard
    Levine, Edward Allen
    Deck, Kenneth B.
    Sington, Jamie
    Law, Wai Lun
    Shbeeb, Imad
    Stork, Lisette
    Marshall, John
    Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial2014In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 3Article in journal (Other academic)
  • 212. Salazar, Ramon
    et al.
    Capdevila, Jaume
    Rosenberg, Robert
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    de Waard, Jan Willem
    Bibeau, Frederic
    Klaase, Joost
    Chang, George J.
    Van Der Hoeven, Jacobus J. M.
    Bachleitner-Hofmann, Thomas
    Midgley, Rachel A.
    Levine, Edward Allen
    Asano, Michio
    Ziebermayr, Reinhard
    Deck, Kenneth B.
    Sington, Jamie
    Law, Wai Lun
    Shbeeb, Imad
    Stork, Lisette
    Marshall, John
    Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial2014In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 15Article in journal (Refereed)
  • 213. Sambade, Clara
    et al.
    Berglund, Mattias
    Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. Onkologi.
    Lagercrantz, Svetlana
    Sällström, Jan
    Reis, Rui M
    Enblad, Gunilla
    Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. Onkologi.
    Glimelius, Bengt
    Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. Onkologi.
    Sundström, Christer
    Department of Genetics and Pathology.
    U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma.2006In: Int J Cancer, ISSN 0020-7136, Vol. 118, no 3, p. 555-63Article in journal (Refereed)
  • 214.
    Sampson, Joshua N.
    et al.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Wheeler, William A.
    Informat Management Serv Inc, Silver Spring, MD USA..
    Yeager, Meredith
    Natl Canc Inst, Div Canc Epidemiol & Genet, Canc Genom Res Lab, Gaithersburg, MD USA..
    Panagiotou, Orestis
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Wang, Zhaoming
    Natl Canc Inst, Div Canc Epidemiol & Genet, Canc Genom Res Lab, Gaithersburg, MD USA..
    Berndt, Sonja I.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Lan, Qing
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Abnet, Christian C.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Amundadottir, Laufey T.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Figueroa, Jonine D.
    Landi, Maria Teresa
    Mirabello, Lisa
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA.;Canc Prevent & Res Inst ISPO, Environm & Occupat Epidemiol Unit, Florence, Italy..
    Savage, Sharon A.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Taylor, Philip R.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    De Vivo, Immaculata
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA..
    McGlynn, Katherine A.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Purdue, Mark P.
    Ontario Hlth Study, Toronto, ON, Canada..
    Rajaraman, Preetha
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Adami, Hans-Olov
    Karolinska Inst, Dept Med Epidemiol & Biostatist, Stockholm, Sweden..
    Ahlbom, Anders
    Karolinska Inst, Inst Environm Med, Dept Epidemiol, S-10401 Stockholm, Sweden..
    Albanes, Demetrius
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Amary, Maria Fernanda
    UCL Canc Inst, London, England.;Royal Natl Orthopaed Hosp NHS Trust, Middlesbrough, Cleveland, England..
    An, She-Juan
    Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China..
    Andersson, Ulrika
    Umea Univ, Dept Radiat Sci Oncol, Umea, Sweden..
    Andriole, Gerald, Jr.
    Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA..
    Andrulis, Irene L.
    Univ Toronto, Litwin Ctr Canc Genet, Toronto, ON, Canada.;Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada..
    Angelucci, Emanuele
    Osped Oncol Riferimento Regionale Businco, Hematol Unit, Cagliari, Italy..
    Ansell, Stephen M.
    Mayo Clin, Dept Med, Rochester, MN USA..
    Arici, Cecilia
    Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy..
    Armstrong, Bruce K.
    Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia..
    Arslan, Alan A.
    NYU, Sch Med, Dept Obstet & Gynecol, New York, NY USA.;NYU, Sch Med, Dept Environm Med, New York, NY USA.;NYU, Sch Med, Dept Populat Hlth, New York, NY USA.;NYU Langone, Med Ctr, Perlmutter Canc Ctr, New York, NY USA..
    Austin, Melissa A.
    Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA..
    Baris, Dalsu
    Barkauskas, Donald A.
    Univ So Calif, Dept Prevent Med, USC Keck Sch Med, Los Angeles, CA 90089 USA..
    Bassig, Bryan A.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA.;Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT USA. German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Baden Wurttembe, Germany..
    Becker, Nikolaus
    Benavente, Yolanda
    Inst Catala Oncol, IDIBELL, Unit Infect & Canc UNIC, Canc Epidemiol Res Programme, Barcelona, Spain.;Ctr Invest Biomed Red Epidemiol Salud Publ CIBERE, Madrid, Spain..
    Benhamou, Simone
    Fdn Jean Dausset Ctr Etude Polymorphisme Humain C, Inst Natl sante & Rech med, U946, Paris, France.;Ctr Natl Receherche Sci, Inst Gustave Roussy, UMR8200, Villejuif, France..
    Berg, Christine
    Natl Canc Inst, Canc Prevent Div, Early Detect Res Grp, Bethesda, MD USA..
    Van Den Berg, David
    Univ So Calif, Dept Prevent Med, USC Keck Sch Med, Los Angeles, CA 90089 USA.;Univ So Calif, Norris Comprehens Canc Ctr, USC Keck Sch Med, Los Angeles, CA USA..
    Bernstein, Leslie
    Beckman Res Inst City Hope, Dept Canc Etiol, Duarte, CA USA..
    Bertrand, Kimberly A.
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA..
    Birmann, Brenda M.
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA..
    Black, Amanda
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Boeing, Heiner
    German Inst Human Nutr, Dept Epidemiol, Potsdam, Germany..
    Boffetta, Paolo
    Tisch Canc Inst, Icahn Sch Med Mt Sinai, New York, NY USA..
    Boutron-Ruault, Marie-Christine
    Univ Paris 11, F-94805 Villejuif, France.;Inst Gustave Roussy, F-94805 Villejuif, France..
    Bracci, Paige M.
    Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA..
    Brinton, Louise
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Brooks-Wilson, Angela R.
    BC Canc Agcy, Genome Sci Ctr, Vancouver, BC, Canada.;Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada..
    Bueno-de-Mesquita, H. Bas
    Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.;Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands..
    Burdett, Laurie
    Natl Canc Inst, Div Canc Epidemiol & Genet, Canc Genom Res Lab, Gaithersburg, MD USA..
    Buring, Julie
    Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA USA.;Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MD 02115 USA.;Harvard Univ, Sch Med, Boston, MD USA..
    Butler, Mary Ann
    NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA..
    Cai, Qiuyin
    Vanderbilt Univ, Ctr Med, Dept Med, Nashville, TN 37232 USA.;Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA..
    Cancel-Tassin, Geraldine
    Ctr Rech Pathol Prostat, Paris, France.;Univ Paris 06, ONCOTYPE URO, GRC 5, Paris, France..
    Canzian, Federico
    German Canc Res Ctr, Genom Epidemiol Grp, Heidelberg, Germany..
    Carrato, Alfredo
    Ramon y Cajal Univ Hosp, Madrid, Spain..
    Carreon, Tania
    NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA..
    Carta, Angela
    Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy..
    Chan, John K. C.
    Queen Elizabeth Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China..
    Chang, Ellen T.
    Stanford Univ, Sch Med, Div Epidemiol, Dept Hlth Res & Policy, Stanford, CA 94305 USA.;Exponent Inc, Ctr Epidemiol & Computat Biol, Hlth Sci, Menlo Pk, CA USA..
    Chang, Gee-Chen
    Natl Yang Ming Univ, Sch Med, Dept Med, Taipei 112, Taiwan.;Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan..
    Chang, I-Shou
    Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan, Taiwan..
    Chang, Jiang
    Chinese Acad Med Sci, Canc Inst & Hosp, Dept Etiol & Carcinogenesis, Beijing 100730, Peoples R China.;Peking Union Med Coll, Beijing 100021, Peoples R China..
    Chang-Claude, Jenny
    Chen, Chien-Jen
    Genom Res Ctr, Taipei, Taiwan..
    Chen, Chih-Yi
    Chung Shan Med Univ, Chung Shan Med Univ Hosp, Dept Surg, Div Thorac Surg,Inst Med, Taichung, Taiwan..
    Chen, Chu
    Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.;Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA..
    Chen, Chung-Hsing
    Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan, Taiwan..
    Chen, Constance
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA..
    Chen, Hongyan
    Fudan Univ, Sch Life Sci, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China..
    Chen, Kexin
    Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Dept Epidemiol & B, Tianjin, Peoples R China..
    Chen, Kuan-Yu
    Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan..
    Chen, Kun-Chieh
    Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan..
    Chen, Ying
    Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore..
    Chen, Ying-Hsiang
    Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan..
    Chen, Yi-Song
    Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan..
    Chen, Yuh-Min
    Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan.;Taipei Med Univ, Taipei Canc Ctr, Taipei, Taiwan..
    Chien, Li-Hsin
    Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan..
    Chirlaque, Maria-Dolores
    Ctr Invest Biomed Red Epidemiol Salud Publ CIBERE, Madrid, Spain.;IMIB Arrixaca, Dept Epidemiol, Murcia Reg Hlth Author, Murcia, Spain..
    Choi, Jin Eun
    Kyungpook Natl Univ, Med Ctr, Canc Res Ctr, Daegu, South Korea..
    Choi, Yi Young
    Kyungpook Natl Univ, Med Ctr, Canc Res Ctr, Daegu, South Korea..
    Chow, Wong-Ho
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Chung, Charles C.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Clavel, Jacqueline
    Univ Paris 11, F-94805 Villejuif, France.;INSERM, Ctr Res Epidemiol & Populat Hlth CESP, U1018, Environm Epidemiol Canc Grp, Villejuif, France..
    Clavel-Chapelon, Franoise
    Ctr Res Epidemiol & Populat Hlth CESP, INSERM, Nutr,Hormones & Womens Hlth team, U1018, F-94805 Villejuif, France.;Univ Paris 11, F-94805 Villejuif, France.;Inst Gustave Roussy, F-94805 Villejuif, France..
    Cocco, Pierluigi
    Univ Cagliari, Dept Publ Hlth Clin & Mol Med, Cagliari, Italy..
    Colt, Joanne S.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Comperat, Eva
    Ctr Rech Pathol Prostat, Paris, France.;Univ Paris 06, ONCOTYPE URO, GRC 5, Paris, France.;AP HP, Pitie Salpetriere, Dept Urol, Paris, France.;AP HP, Pitie Salpetriere, Dept Pathol, Paris, France..
    Conde, Lucia
    Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.;Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.;Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA.;BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada..
    Connors, Joseph M.
    Univ British Columbia, Dept Med, Vancouver, BC, Canada..
    Conti, David
    Univ So Calif, Dept Prevent Med, USC Keck Sch Med, Los Angeles, CA 90089 USA.;Univ So Calif, Norris Comprehens Canc Ctr, USC Keck Sch Med, Los Angeles, CA USA..
    Cortessis, Victoria K.
    Univ So Calif, Dept Prevent Med, USC Keck Sch Med, Los Angeles, CA 90089 USA.;Univ So Calif, Norris Comprehens Canc Ctr, USC Keck Sch Med, Los Angeles, CA USA.;Univ So Calif, Dept Obstet & Gynecol, Los Angeles, CA 90089 USA..
    Cotterchio, Michelle
    Canc Care Ontario, Toronto, ON, Canada.;Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada..
    Cozen, Wendy
    Univ So Calif, Dept Prevent Med, USC Keck Sch Med, Los Angeles, CA 90089 USA.;Univ So Calif, Norris Comprehens Canc Ctr, USC Keck Sch Med, Los Angeles, CA USA..
    Crouch, Simon
    Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England..
    Crous-Bou, Marta
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA..
    Cussenot, Olivier
    Ctr Rech Pathol Prostat, Paris, France.;Univ Paris 06, ONCOTYPE URO, GRC 5, Paris, France.;Hop Tenon, AP HP, Dept Urol, F-75970 Paris, France..
    Davis, Faith G.
    Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada..
    Ding, Ti
    Shanxi Canc Hosp, Taiyuan, Shanxi, Peoples R China..
    Diver, W. Ryan
    Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA..
    Dorronsoro, Miren
    Ctr Invest Biomed Red Epidemiol Salud Publ CIBERE, Madrid, Spain.;BioDonostia Res Inst, Dept Hlth, Basque Region, Spain..
    Dossus, Laure
    Ctr Res Epidemiol & Populat Hlth CESP, INSERM, Nutr,Hormones & Womens Hlth team, U1018, F-94805 Villejuif, France.;Univ Paris 11, F-94805 Villejuif, France.;Inst Gustave Roussy, F-94805 Villejuif, France..
    Duell, Eric J.
    Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Canc Epidemiol Res Program, Unit Nutr Environm & Canc, Barcelona, Spain..
    Ennas, Maria Grazia
    Univ Cagliari, Dept Biomed Sci, Cagliari, Italy..
    Erickson, Ralph L.
    Walter Reed Army Inst Res, Silver Spring, MD USA..
    Feychting, Maria
    Karolinska Inst, Inst Environm Med, Dept Epidemiol, S-10401 Stockholm, Sweden..
    Flanagan, Adrienne M.
    UCL Canc Inst, London, England.;Royal Natl Orthopaed Hosp NHS Trust, Middlesbrough, Cleveland, England..
    Foretova, Lenka
    Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno, Czech Republic.;MF MU, Brno, Czech Republic..
    Fraumeni, Joseph F., Jr.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Freedman, Neal D.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Freeman, Laura E. Beane
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Fuchs, Charles
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA.;Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA..
    Gago-Dominguez, Manuela
    Inst Invest Sanitaria de Santiago, Serv Galego Saude SERGAS, Galician Fdn Genom Med, Genom Med Grp, Santiago De Compostela, Spain..
    Gallinger, Steven
    Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada..
    Gao, Yu-Tang
    Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China..
    Gapstur, Susan M.
    Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA..
    Garcia-Closas, Montserrat
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA.;Inst Canc Res, Div Genet & Epidemiol, London, England..
    Garcia-Closas, Reina
    Hosp Univ Canarias, Unidad Invest, San Cristobal la Laguna, Spain..
    Gascoyne, Randy D.
    Univ British Columbia, Dept Pathol, Vancouver, BC, Canada..
    Gastier-Foster, Julie
    Nationwide Childrens Hosp, Columbus, OH USA.;Ohio State Univ, Dept Pathol & Pediat, Columbus, OH 43210 USA..
    Gaudet, Mia M.
    Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA..
    Gaziano, J. Michael
    Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA USA.;Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MD 02115 USA.;Harvard Univ, Sch Med, Boston, MD USA.;Vet Affairs Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA..
    Giffen, Carol
    Informat Management Serv Inc, Silver Spring, MD USA..
    Giles, Graham G.
    Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.;Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Biostat & Epidemiol, Carlton, Vic 3053, Australia..
    Giovannucci, Edward
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA..
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology. Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden..
    Goggins, Michael
    Sidney Kimmel Canc Ctr, Dept Oncol, Baltimore, MD USA.;Johns Hopkins Univ, Baltimore, MD USA.;Sidney Kimmel Canc Ctr, Dept Pathol, Baltimore, MD USA.;Sidney Kimmel Canc Ctr, Dept Med, Baltimore, MD USA..
    Gokgoz, Nalan
    Univ Toronto, Litwin Ctr Canc Genet, Toronto, ON, Canada.;Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada..
    Goldstein, Alisa M.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Gorlick, Richard
    Childrens Hosp Montefiore, Albert Einstein Coll Med, Bronx, NY USA..
    Gross, Myron
    Univ Minnesota, Lab Med & Pathol, Minneapolis, MN USA..
    Grubb, Robert, III
    Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA..
    Gu, Jian
    Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA..
    Guan, Peng
    China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang 110001, Peoples R China..
    Gunter, Marc
    Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England..
    Guo, Huan
    Huazhong Univ Sci & Technol, Sch Publ Hlth, Inst Occupat Med, Wuhan 430074, Peoples R China.;Huazhong Univ Sci & Technol, Sch Publ Hlth, Minist Educ, Key Lab Environm & Hlth, Wuhan 430074, Peoples R China..
    Habermann, Thomas M.
    Mayo Clin, Dept Med, Rochester, MN USA..
    Haiman, Christopher A.
    Halai, Dina
    UCL Canc Inst, London, England.;Royal Natl Orthopaed Hosp NHS Trust, Middlesbrough, Cleveland, England..
    Hallmans, Goran
    Umea Univ, Dept Publ Hlth & Clin Med, Nutr Res, Umea, Sweden..
    Hassan, Manal
    Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA..
    Hattinger, Claudia
    He, Qincheng
    China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang 110001, Peoples R China..
    He, Xingzhou
    Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China..
    Helzlsouer, Kathy
    Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA..
    Henderson, Brian
    Univ So Calif, Dept Prevent Med, USC Keck Sch Med, Los Angeles, CA 90089 USA..
    Henriksson, Roger
    Umea Univ, Dept Radiat Sci Oncol, Umea, Sweden..
    Hjalgrim, Henrik
    Statens Serum Inst, Dept Epidemiol Res, Div Hlth Surveillance & Res, DK-2300 Copenhagen, Denmark..
    Hoffman-Bolton, Judith
    Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA..
    Hohensee, Chancellor
    Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA..
    Holford, Theodore R.
    Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA..
    Holly, Elizabeth A.
    Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA..
    Hong, Yun-Chul
    Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea..
    Hoover, Robert N.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Horn-Ross, Pamela L.
    Canc Prevent Inst Calif, Fremont, CA USA..
    Hosain, G. M. Monawar
    New Hampshire State Canc Registry, Concord, NH USA..
    Hosgood, H. Dean, III
    Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA..
    Hsiao, Chin-Fu
    Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan.;Natl Hlth Res Inst, Taiwan Lung Canc Tissue Specimen Informat Resourc, Zhunan, Taiwan..
    Hu, Nan
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Hu, Wei
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Hu, Zhibin
    Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Nanjing, Jiangsu, Peoples R China.;Nanjing Med Univ, Sch Publ Hlth, Ctr Canc, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Jiangsu, Peoples R China..
    Huang, Ming-Shyan
    Kaohsiung Med Univ, Sch Med, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan..
    Huerta, Jose-Maria
    IMIB Arrixaca, Dept Epidemiol, Murcia Reg Hlth Author, Murcia, Spain..
    Hung, Jen-Yu
    Kaohsiung Med Univ, Sch Med, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan..
    Hutchinson, Amy
    Natl Canc Inst, Div Canc Epidemiol & Genet, Canc Genom Res Lab, Gaithersburg, MD USA..
    Inskip, Peter D.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Jackson, Rebecca D.
    Ohio State Univ, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA..
    Jacobs, Eric J.
    Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA..
    Jenab, Mazda
    Int Agcy Res Canc, F-69372 Lyon, France..
    Jeon, Hyo-Sung
    Kyungpook Natl Univ, Mol Diagnost & Imaging Ctr, Daegu, South Korea..
    Ji, Bu-Tian
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Jin, Guangfu
    Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Nanjing, Jiangsu, Peoples R China.;Nanjing Med Univ, Sch Publ Hlth, Ctr Canc, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Jiangsu, Peoples R China..
    Jin, Li
    Fudan Univ, Sch Life Sci, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China..
    Johansen, Christoffer
    Danish Canc Soc Res Ctr, Unit Survivorship, Copenhagen, Denmark..
    Johnson, Alison
    Vermont Canc Registry, Burlington, VT USA..
    Jung, Yoo Jin
    Seoul Natl Univ, Coll Med, Canc Res Inst, Dept Thorac & Cardiovasc Surg, Seoul, South Korea..
    Kaaks, Rudolph
    Kamineni, Aruna
    Grp Hlth Res Inst, Seattle, WA USA..
    Kane, Eleanor
    Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England..
    Kang, Chang Hyun
    Seoul Natl Univ, Coll Med, Canc Res Inst, Dept Thorac & Cardiovasc Surg, Seoul, South Korea..
    Karagas, Margaret R.
    Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA..
    Kelly, Rachel S.
    Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.;Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, MRC PHE Ctr Environm & Hlth, London, England..
    Khaw, Kay-Tee
    Univ Cambridge, Cambridge CB2 1TN, England..
    Kim, Christopher
    Kim, Hee Nam
    Chonnam Natl Univ, Ctr Creat Biomed Scientists, Gwangju, South Korea..
    Kim, Jin Hee
    Seoul Natl Univ, Grad Sch Publ Hlth, Dept Environm Hlth, Seoul, South Korea..
    Kim, Jun Suk
    Korea Univ, Guro Hosp, Coll Med, Dept Internal Med,Div Med Oncol, Seoul, South Korea..
    Kim, Yeul Hong
    Korea Univ, Coll Med, Anam Hosp, Div Hematol Oncol,Dept Internal Med, Seoul 136705, South Korea..
    Kim, Young Tae
    Seoul Natl Univ, Coll Med, Canc Res Inst, Dept Thorac & Cardiovasc Surg, Seoul, South Korea..
    Kim, Young-Chul
    Chonnam Natl Univ, Hwasun Hosp, Lung & Esophageal Canc Clin, Hwasun Eup, South Korea.;Chonnam Natl Univ, Sch Med, Dept Internal Med, Gwangju, South Korea..
    Kitahara, Cari M.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Klein, Alison P.
    Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.;Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA..
    Klein, Robert J.
    Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA..
    Kogevinas, Manolis
    Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.;Hosp del Mar, Municipal Inst Med Res IMIM, Barcelona, Spain.;Natl Sch Publ Hlth, Athens, Greece..
    Kohno, Takashi
    Natl Canc Ctr, Res Inst, Div Genome Biol, Tokyo 104, Japan..
    Kolonel, Laurence N.
    Canc Res Ctr Hawaii, Honolulu, HI USA..
    Kooperberg, Charles
    Kricker, Anne
    Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia..
    Krogh, Vittorio
    Fdn IRCCS Ist Nazl Tumori, Epidemiol & Prevent Unit, Milan, Italy..
    Kunitoh, Hideo
    Japanese Red Cross Med Ctr, Dept Med Oncol, Tokyo, Japan..
    Kurtz, Robert C.
    Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA..
    Kweon, Sun-Seog
    Chonnam Natl Univ, Hwasun Hosp, Jeonnam Reg Canc Ctr, Hwasun Eup, South Korea.;Chonnam Natl Univ, Sch Med, Dept Prevent Med, Gwangju, South Korea..
    LaCroix, Andrea
    Lawrence, Charles
    Westat Corp, Rockville, MD USA..
    Lecanda, Fernando
    Univ Navarra, Univ Navarra Clin, Dept Pediat, Pamplona, Spain..
    Lee, Victor Ho Fun
    Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China..
    Li, Donghui
    Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA..
    Li, Haixin
    Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Dept Epidemiol & B, Tianjin, Peoples R China..
    Li, Jihua
    Li, Yao-Jen
    Genom Res Ctr, Taipei, Taiwan..
    Li, Yuqing
    Canc Prevent Inst Calif, Fremont, CA USA..
    Liao, Linda M.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Liebow, Mark
    Mayo Clin, Dept Med, Rochester, MN USA..
    Lightfoot, Tracy
    Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England..
    Lim, Wei-Yen
    Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore..
    Lin, Chien-Chung
    Natl Cheng Kung Univ, Cheng Kung Univ Med Coll & Hosp, Dept Internal Med, Tainan 701, Taiwan..
    Lin, Dongxin
    Chinese Acad Med Sci, Canc Inst & Hosp, Dept Etiol & Carcinogenesis, Beijing 100730, Peoples R China.;Peking Union Med Coll, Beijing 100021, Peoples R China..
    Lindstrom, Sara
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA..
    Linet, Martha S.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Link, Brian K.
    Liu, Chenwei
    Natl Canc Inst, Div Canc Epidemiol & Genet, Canc Genom Res Lab, Gaithersburg, MD USA..
    Liu, Jianjun
    Qujing Ctr Dis Control & Prevent, Sanjiangdadao, Qujing, Peoples R China.;Genome Inst Singapore, Human Genet, Singapore, Singapore..
    Liu, Li
    Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Wuhan 430074, Peoples R China. Umea Univ, Dept Surg & Perioperat Sci Urol & Androl, Umea, Sweden. Univ Florence, Dept Surg & Translat Med, Sect Anatomopathol, Florence, Italy..
    Ljungberg, Boerje
    Lloreta, Josep
    Ctr Invest Biomed Red Epidemiol Salud Publ CIBERE, Madrid, Spain..
    Di Lollo, Simonetta
    Lu, Daru
    Fudan Univ, Sch Life Sci, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China..
    Lund, Eiluv
    Univ Tromso, Arctic Univ Norway, Fac Hlth Sci, Dept Community Med, Tromso, Norway. Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Madrid, Spain..
    Malats, Nuria
    Mannisto, Satu
    Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland..
    Le Marchand, Loic
    Univ Hawaii, Ctr Canc, Canc Epidemiol Program, Honolulu, HI 96822 USA. Stanford Univ, Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA..
    Marina, Neyssa
    Masala, Giovanna
    Canc Res & Prevent Inst ISPO, Mol & Nutr Epidemiol Unit, Florence, Italy..
    Mastrangelo, Giuseppe
    Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy..
    Matsuo, Keitaro
    Aichi Canc Res Inst, Div Mol Med, Nagoya, Aichi, Japan..
    Maynadie, Marc
    Univ Burgundy, Registre Hemopathies Malignes Cote dOr, EA 4184, Dijon, France.;Dijon Univ Hosp, Dijon, France..
    Mckay, James
    Int Agcy Res Canc, F-69372 Lyon, France..
    McKean-Cowdin, Roberta
    Univ So Calif, Dept Prevent Med, USC Keck Sch Med, Los Angeles, CA 90089 USA..
    Melbye, Mads
    Statens Serum Inst, Dept Epidemiol Res, Div Hlth Surveillance & Res, DK-2300 Copenhagen, Denmark.;Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA. Brown Univ, Dept Epidemiol, Div Biol & Med, Providence, RI 02912 USA..
    Melin, Beatrice S.
    Umea Univ, Dept Radiat Sci Oncol, Umea, Sweden..
    Michaud, Dominique S.
    Mitsudomi, Tetsuya
    Kinki Univ, Sch Med, Div Thorac Surg, Sayama, Osaka 589, Japan..
    Monnereau, Alain
    Univ Paris 11, F-94805 Villejuif, France.;INSERM, Ctr Res Epidemiol & Populat Hlth CESP, U1018, Environm Epidemiol Canc Grp, Villejuif, France.;Inst Bergonie, Registre Hemopathies Malignes Gironde, Bordeaux, France. Aarhus Univ, Epidemiol Sect, DK-8000 Aarhus C, Denmark. Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark..
    Montalvan, Rebecca
    Westat Corp, Rockville, MD USA..
    Moore, Lee E.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Mortensen, Lotte Maxild
    Nieters, Alexandra
    Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Baden Wurttembe, Germany..
    North, Kari E.
    Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.;Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA..
    Novak, Anne J.
    Mayo Clin, Dept Med, Rochester, MN USA..
    Oberg, Ann L.
    Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN USA..
    Offit, Kenneth
    Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA..
    Oh, In-Jae
    Chonnam Natl Univ, Hwasun Hosp, Lung & Esophageal Canc Clin, Hwasun Eup, South Korea.;Chonnam Natl Univ, Sch Med, Dept Internal Med, Gwangju, South Korea..
    Olson, Sara H.
    Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA..
    Palli, Domenico
    Canc Res & Prevent Inst ISPO, Mol & Nutr Epidemiol Unit, Florence, Italy..
    Pao, William
    Vanderbilt Univ, Med Ctr, Div Hematol & Oncol, Nashville, TN 37235 USA..
    Park, In Kyu
    Seoul Natl Univ, Coll Med, Canc Res Inst, Dept Thorac & Cardiovasc Surg, Seoul, South Korea..
    Park, Jae Yong
    Kyungpook Natl Univ, Med Ctr, Lung Canc Ctr, Daegu, South Korea..
    Park, Kyong Hwa
    Korea Univ, Coll Med, Anam Hosp, Div Hematol Oncol,Dept Internal Med, Seoul 136705, South Korea..
    Patino-Garcia, Ana
    Univ Navarra, Univ Navarra Clin, Dept Pediat, Pamplona, Spain..
    Pavanello, Sofia
    Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy..
    Peeters, Petra H. M.
    Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England.;Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care 194, Utrecht, Netherlands.;Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Primary Care & Publ Hlth, London, England..
    Perng, Reury-Perng
    Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan..
    Peters, Ulrike
    Petersen, Gloria M.
    Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Rochester, MN USA..
    Picci, Piero
    Orthopaed Rizzoli Inst, Expt Oncol Lab, Bologna, Italy..
    Pike, Malcolm C.
    Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA..
    Porru, Stefano
    Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy..
    Prescott, Jennifer
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA..
    Prokunina-Olsson, Ludmila
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Qian, Biyun
    Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan..
    Qiao, You-Lin
    Chinese Acad Med Sci, Canc Inst & Hosp, Dept Epidemiol, Beijing 100730, Peoples R China..
    Rais, Marco
    Univ Cagliari, Dept Publ Hlth Clin & Mol Med, Cagliari, Italy..
    Riboli, Elio
    Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.;Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England..
    Riby, Jacques
    Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.;Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.;Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA.;BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada..
    Risch, Harvey A.
    Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA..
    Rizzato, Cosmeri
    German Canc Res Ctr, Genom Epidemiol Grp, Heidelberg, Germany..
    Rodabough, Rebecca
    Roman, Eve
    Roupret, Morgan
    Ctr Rech Pathol Prostat, Paris, France.;Univ Paris 06, ONCOTYPE URO, GRC 5, Paris, France.;AP HP, Pitie Salpetriere, Dept Urol, Paris, France..
    Ruder, Avima M.
    NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA..
    de Sanjose, Silvia
    Inst Catala Oncol, IDIBELL, Unit Infect & Canc UNIC, Canc Epidemiol Res Programme, Barcelona, Spain..
    Scelo, Ghislaine
    Int Agcy Res Canc, F-69372 Lyon, France..
    Schned, Alan
    Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA..
    Schumacher, Fredrick
    Univ So Calif, Dept Prevent Med, USC Keck Sch Med, Los Angeles, CA 90089 USA..
    Schwartz, Kendra
    Orthopaed Rizzoli Inst, Expt Oncol Lab, Bologna, Italy..
    Schwenn, Molly
    Maine Canc Registry, Augusta, ME USA..
    Scotlandi, Katia
    Seow, Adeline
    Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore..
    Serra, Consol
    Univ Pompeu Fabra, Dept Ciencies Experimentals & Salut, Barcelona, Spain..
    Serra, Massimo
    Orthopaed Rizzoli Inst, Expt Oncol Lab, Bologna, Italy..
    Sesso, Howard D.
    Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.;Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA USA.;Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MD 02115 USA.;Harvard Univ, Sch Med, Boston, MD USA..
    Setiawan, Veronica Wendy
    Univ So Calif, Dept Prevent Med, USC Keck Sch Med, Los Angeles, CA 90089 USA..
    Severi, Gianluca
    Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.;Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Biostat & Epidemiol, Carlton, Vic 3053, Australia.;Human Genet Fdn, Turin, Italy..
    Severson, Richard K.
    Wayne State Univ, Dept Family Med & Publ Hlth Sci, Detroit, MI USA. Karmanos Canc Inst, Detroit, MI USA..
    Shanafelt, Tait D.
    Mayo Clin, Dept Med, Rochester, MN USA..
    Shen, Hongbing
    Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Nanjing, Jiangsu, Peoples R China.;Nanjing Med Univ, Sch Publ Hlth, Ctr Canc, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Jiangsu, Peoples R China..
    Shen, Wei
    Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Nanjing, Jiangsu, Peoples R China.;Nanjing Med Univ, Sch Publ Hlth, Ctr Canc, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Jiangsu, Peoples R China..
    Shin, Min-Ho
    Chonnam Natl Univ, Sch Med, Dept Prevent Med, Gwangju, South Korea..
    Shiraishi, Kouya
    Shu, Xiao-Ou
    Vanderbilt Univ, Ctr Med, Dept Med, Nashville, TN 37232 USA.;Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA..
    Siddiq, Afshan
    Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England..
    Sierrasesumaga, Luis
    Univ Navarra, Univ Navarra Clin, Dept Pediat, Pamplona, Spain..
    Sihoe, Alan Dart Loon
    Queen Mary Hosp, Div Cardiothorac Surg, Dept Surg, Hong Kong, Hong Kong, Peoples R China. Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia..
    Skibola, Christine F.
    Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.;Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.;Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA.;BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada..
    Smith, Alex
    Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England..
    Smith, Martyn T.
    Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA.;BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada..
    Southey, Melissa C.
    Spinelli, John J.
    BC Canc Agcy, Canc Control Res, Vancouver, BC, Canada.;Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada..
    Staines, Anthony
    Dublin City Univ, Sch Nursing & Human Sci, Dublin 9, Ireland..
    Stampfer, Meir
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA..
    Stern, Marianna C.
    Stevens, Victoria L.
    Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA..
    Stolzenberg-Solomon, Rachael S.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Su, Jian
    Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China..
    Su, Wu-Chou
    Natl Cheng Kung Univ, Med Coll & Hosp, Tainan 701, Taiwan..
    Sund, Malin
    Umea Univ, Dept Surg & Perioperat Sci, Surg, Umea, Sweden..
    Sung, Jae Sook
    Korea Univ, Canc Res Inst, Seoul, South Korea..
    Sung, Sook Whan
    Seoul St Marys Hosp, Dept Thorac & Cardiovasc Surg, Seoul, South Korea..
    Tan, Wen
    Chinese Acad Med Sci, Canc Inst & Hosp, Dept Etiol & Carcinogenesis, Beijing 100730, Peoples R China.;Peking Union Med Coll, Beijing 100021, Peoples R China..
    Tang, Wei
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Tardon, Adonina
    Ctr Invest Biomed Red Epidemiol Salud Publ CIBERE, Madrid, Spain.;Univ Oviedo, Inst Univ Oncol, Oviedo, Spain..
    Thomas, David
    St Vincents Hosp, Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia..
    Thompson, Carrie A.
    Mayo Clin, Dept Med, Rochester, MN USA..
    Tinker, Lesley F.
    Tirabosco, Roberto
    Royal Natl Orthopaed Hosp NHS Trust, Middlesbrough, Cleveland, England..
    Tjonneland, Anne
    Danish Canc Soc, Res Ctr, Copenhagen, Denmark..
    Travis, Ruth C.
    Univ Oxford, Canc Epidemiol Unit, Oxford, England..
    Trichopoulos, Dimitrios
    Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.;Acad Athens, Bur Epidemiol Res, Athens, Greece.;Hellen Hlth Fdn, Athens, Greece..
    Tsai, Fang-Yu
    Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan, Taiwan..
    Tsai, Ying-Huang
    Chang Gung Mem Hosp, Dept Resp Thearpy, Chiayi, Taiwan..
    Tucker, Margaret
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Turner, Jenny
    Macquarie Univ, Australian Sch Adv Med, Sydney, NSW 2109, Australia.;Douglass Hanly Moir Pathol, Dept Histopathol, Macquarie Pk, NSW, Australia..
    Vajdic, Claire M.
    Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW, Australia..
    Vermeulen, Roel C. H.
    Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care 194, Utrecht, Netherlands.;Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands..
    Villano, Danylo J.
    Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA..
    Vineis, Paolo
    Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, MRC PHE Ctr Environm & Hlth, London, England.;Human Genet Fdn, Turin, Italy..
    Virtamo, Jarmo
    Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.;Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland..
    Visvanathan, Kala
    Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA..
    Wactawski-Wende, Jean
    China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang 110001, Peoples R China.;SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA..
    Wang, Chaoyu
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Wang, Chih-Liang
    Chang Gung Mem Hosp, Dept Pulm & Crit Care, Taoyuan, Taiwan..
    Wang, Jiu-Cun
    Fudan Univ, Sch Life Sci, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China.;Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China..
    Wang, Junwen
    Univ Hong Kong, Li Ka Shing Fac Med, Ctr Genom Sci, Hong Kong, Peoples R China.;Univ Hong Kong, Li Ka Shing Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China..
    Wei, Fusheng
    China Natl Environm Monitoring Ctr, Beijing, Peoples R China..
    Weiderpass, Elisabete
    Karolinska Inst, Dept Med Epidemiol & Biostatist, Stockholm, Sweden.;Univ Tromso, Arctic Univ Norway, Fac Hlth Sci, Dept Community Med, Tromso, Norway. Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Madrid, Spain.;Canc Registry Norway, Oslo, Norway.;Folkhalsan Res Ctr, Dept Genet Epidemiol, Helsinki, Finland..
    Weiner, George J.
    Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA USA..
    Weinstein, Stephanie
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Wentzensen, Nicolas
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    White, Emily
    Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA..
    Witzig, Thomas E.
    Mayo Clin, Dept Med, Rochester, MN USA..
    Wolpin, Brian M.
    Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.;Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA USA..
    Wong, Maria Pik
    Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China..
    Wu, Chen
    Chinese Acad Med Sci, Canc Inst & Hosp, Dept Etiol & Carcinogenesis, Beijing 100730, Peoples R China.;Peking Union Med Coll, Beijing 100021, Peoples R China.;Chinese Acad Med Sci, Canc Inst & Hosp, State Key Lab Mol Oncol, Beijing 100730, Peoples R China.;Peking Union Med Coll, Beijing 100021, Peoples R China..
    Wu, Guoping
    China Natl Environm Monitoring Ctr, Beijing, Peoples R China..
    Wu, Junjie
    Fudan Univ, Sch Life Sci, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China..
    Wu, Tangchun
    Huazhong Univ Sci & Technol, Sch Publ Hlth, Inst Occupat Med, Wuhan 430074, Peoples R China.;Huazhong Univ Sci & Technol, Sch Publ Hlth, Minist Educ, Key Lab Environm & Hlth, Wuhan 430074, Peoples R China..
    Wu, Wei
    Wu, Xifeng
    Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA..
    Wu, Yi-Long
    Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China..
    Wunder, Jay S.
    Univ Toronto, Litwin Ctr Canc Genet, Toronto, ON, Canada.;Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada..
    Xiang, Yong-Bing
    Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Canc Inst, Shanghai 200030, Peoples R China..
    Xu, Jun
    Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China..
    Xu, Ping
    Wuhan Iron & Steel Corp Staff Worker Hosp, Dept Oncol, Wuhan, Peoples R China..
    Yang, Pan-Chyr
    Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan..
    Yang, Tsung-Ying
    Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan..
    Ye, Yuanqing
    Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA..
    Yin, Zhihua
    China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang 110001, Peoples R China..
    Yokota, Jun
    Inst Predict & Personalized Med Canc IMPPC, Barcelona, Spain..
    Yoon, Ho-Il
    Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea..
    Yu, Chong-Jen
    Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan..
    Yu, Herbert
    Univ Hawaii, Ctr Canc, Canc Epidemiol Program, Honolulu, HI 96822 USA. Stanford Univ, Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA..
    Yu, Kai
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Yuan, Jian-Min
    Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. Georgetown Univ, Med Ctr, Innovat Ctr Biomed Informat, Washington, DC USA. Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA..
    Zelenetz, Andrew
    NYU, Sch Med, Dept Environm Med, New York, NY USA.;NYU, Sch Med, Dept Populat Hlth, New York, NY USA.;NYU Langone, Med Ctr, Perlmutter Canc Ctr, New York, NY USA.;Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA..
    Zeleniuch-Jacquotte, Anne
    Zhang, Xu-Chao
    Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China..
    Zhang, Yawei
    Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT USA. German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Baden Wurttembe, Germany..
    Zhao, Xueying
    Fudan Univ, Sch Life Sci, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China..
    Zhao, Zhenhong
    Fudan Univ, Sch Life Sci, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China..
    Zheng, Hong
    Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Dept Epidemiol & B, Tianjin, Peoples R China..
    Zheng, Tongzhang
    Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT USA. German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Baden Wurttembe, Germany..
    Zheng, Wei
    Vanderbilt Univ, Ctr Med, Dept Med, Nashville, TN 37232 USA.;Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA..
    Zhou, Baosen
    China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang 110001, Peoples R China..
    Zhu, Meng
    Zucca, Mariagrazia
    Boca, Simina M.
    Cerhan, James R.
    Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA..
    Ferri, Giovanni M.
    Univ Bari, Interdisciplinary Dept Med, Bari, Italy..
    Hartge, Patricia
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Hsiung, Chao Agnes
    Magnani, Corrado
    Univ Piemonte Orientale, Dept Translat Med, CPO Piemonte & Unit Med Stat & Epidemiol, Novara, Italy..
    Miligi, Lucia
    Morton, Lindsay M.
    Smedby, Karin E.
    Karolinska Univ Hosp, Karolinska Inst, Dept Med, Stockholm, Sweden..
    Teras, Lauren R.
    Vijai, Joseph
    Wang, Sophia S.
    Beckman Res Inst City Hope, Dept Canc Etiol, Duarte, CA USA..
    Brennan, Paul
    Int Agcy Res Canc, F-69372 Lyon, France..
    Caporaso, Neil E.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Hunter, David J.
    Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.;Harvard Univ, Sch Med, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.;Broad Inst Harvard, Cambridge, MA USA.;MIT, Cambridge, MA 02139 USA..
    Kraft, Peter
    Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.;Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA..
    Rothman, Nathaniel
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Silverman, Debra T.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Slager, Susan L.
    Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA..
    Chanock, Stephen J.
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Chatterjee, Nilanjan
    NCI, Div Canc Epidemiol & Genet, Bethesda, MD USA..
    Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types2015In: Journal of the National Cancer Institute, ISSN 0027-8874, E-ISSN 1460-2105, Vol. 107, no 12, article id djv279Article in journal (Refereed)
    Abstract [en]

    Background: Studies of related individuals have consistently demonstrated notable familial aggregation of cancer. We aim to estimate the heritability and genetic correlation attributable to the additive effects of common single-nucleotide polymorphisms (SNPs) for cancer at 13 anatomical sites. Methods: Between 2007 and 2014, the US National Cancer Institute has generated data from genome-wide association studies (GWAS) for 49 492 cancer case patients and 34 131 control patients. We apply novel mixed model methodology (GCTA) to this GWAS data to estimate the heritability of individual cancers, as well as the proportion of heritability attributable to cigarette smoking in smoking-related cancers, and the genetic correlation between pairs of cancers. Results: GWAS heritability was statistically significant at nearly all sites, with the estimates of array-based heritability, h(l)(2), on the liability threshold (LT) scale ranging from 0.05 to 0.38. Estimating the combined heritability of multiple smoking characteristics, we calculate that at least 24% (95% confidence interval [CI] = 14% to 37%) and 7% (95% CI = 4% to 11%) of the heritability for lung and bladder cancer, respectively, can be attributed to genetic determinants of smoking. Most pairs of cancers studied did not show evidence of strong genetic correlation. We found only four pairs of cancers with marginally statistically significant correlations, specifically kidney and testes (rho = 0.73, SE = 0.28), diffuse large B-cell lymphoma (DLBCL) and pediatric osteosarcoma (rho = 0.53, SE = 0.21), DLBCL and chronic lymphocytic leukemia (CLL) (rho = 0.51, SE = 0.18), and bladder and lung (rho = 0.35, SE = 0.14). Correlation analysis also indicates that the genetic architecture of lung cancer differs between a smoking population of European ancestry and a nonsmoking Asian population, allowing for the possibility that the genetic etiology for the same disease can vary by population and environmental exposures. Conclusion: Our results provide important insights into the genetic architecture of cancers and suggest new avenues for investigation.

  • 215. Sandin, Sven
    et al.
    Hjalgrim, Henrik
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
    Rostgaard, Klaus
    Pukkala, Eero
    Askling, Johan
    Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was2006In: Cancer Epidemiology, Biomarkers and Prevention, ISSN 1055-9965, E-ISSN 1538-7755, Vol. 15, no 7, p. 1295-1300Article in journal (Refereed)
    Abstract [en]

    Background: Reports during the early 1990s indicated non-Hodgkin's lymphoma (NHL) as one of the most rapidly increasing malignancies. More recent trends remain poorly characterized, as do the underlying reasons for NHL time trends, in particular, the effect of changes in classification and registration of lymphoproliferative malignancies. Insights into the descriptive epidemiology of NHL may shed light upon its elusive etiology. Methods: We used data from the Swedish, Danish, and Finnish national cancer registers to assess the incidences of NHL and other lymphoproliferative malignancies between 1960 and 2004. Using Poisson regression, we estimated the annual rate of change in NHL incidence per decade by sex, age, and country. Results: In Sweden, Denmark, and Finland, the NHL incidence increased in both genders and all age categories by about 4% every year up until the early 1990s. Thereafter, the incidence increased at a slower rate (ages 60-79 years), stabilized (ages 50-59 and >= 80 years), and decreased (ages 0-49 years), respectively, similarly for males and females in the three countries. Time trends of NHL were not reciprocated and explained by trends for other lymphoproliferative malignancies nor explained by trends in NHL as secondary primaries or NHL diagnosed postmortem. Conclusions: The epidemic increase of NHL has recently subsided. Changes in the classification of lymphoproliferative malignancies, or occurrence of NHL as second primaries, only offer a marginal explanation.

  • 216.
    Schernberg, A.
    et al.
    Hosp Tenon, Serv Oncol Radiotherapie, Paris, France..
    Vernerey, D.
    Univ Hosp Besancon, INSERM, UMR 1098, Methodol & Qual Life Oncol Unit, Besancon, France..
    Goldstein, D.
    Kinghorn Canc Ctr, Sydney, NSW, Australia.;Garvan Inst Med Res, Sydney, NSW, Australia..
    Van Laethem, J. L.
    Hop Erasme, Brussels, Belgium..
    Van Houtte, P. J.
    Inst Bordet, Brussels, Belgium..
    Bonnetain, F.
    Univ Hosp Besancon, INSERM, UMR 1098, Methodol & Qual Life Oncol Unit, Besancon, France..
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Louvet, C.
    Inst Mutualiste Montsouris, Dept Med Oncol, Paris, France..
    Hammel, P.
    Hop Beaujon, Serv Gastroenterol, Clichy, France..
    Huguet, F.
    Hosp Tenon, Serv Oncol Radiotherapie, Paris, France..
    Neutrophils Predicting Tumor Local Control After Chemoradiation Therapy in Locally Advanced Pancreatic Carcinoma in the LAP 07 Trial2017In: International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, E-ISSN 1879-355X, Vol. 99, no 2, p. S88-S89Article in journal (Other academic)
  • 217. Schmoll, H. J.
    et al.
    Van Cutsem, E.
    Stein, A.
    Valentini, V.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Haustermans, K.
    Nordlinger, B.
    van de Velde, C. J.
    Balmana, J.
    Regula, J.
    Nagtegaal, I. D.
    Beets-Tan, R. G.
    Arnold, D.
    Ciardiello, F.
    Hoff, P.
    Kerr, D.
    Koehne, C. H.
    Labianca, R.
    Price, T.
    Scheithauer, W.
    Sobrero, A.
    Tabernero, J.
    Aderka, D.
    Barroso, S.
    Bodoky, G.
    Douillard, J. Y.
    El Ghazaly, H.
    Gallardo, J.
    Garin, A.
    Glynne-Jones, R.
    Jordan, K.
    Meshcheryakov, A.
    Papamichail, D.
    Pfeiffer, P.
    Souglakos, I.
    Turhal, S.
    Cervantes, A.
    ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making2012In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 23, no 10, p. 2479-2516Article in journal (Refereed)
    Abstract [en]

    Colorectal cancer (CRC) is the most common tumour type in both sexes combined in Western countries. Although screening programmes including the implementation of faecal occult blood test and colonoscopy might be able to reduce mortality by removing precursor lesions and by making diagnosis at an earlier stage, the burden of disease and mortality is still high. Improvement of diagnostic and treatment options increased staging accuracy, functional outcome for early stages as well as survival. Although high quality surgery is still the mainstay of curative treatment, the management of CRC must be a multi-modal approach performed by an experienced multi-disciplinary expert team. Optimal choice of the individual treatment modality according to disease localization and extent, tumour biology and patient factors is able to maintain quality of life, enables long-term survival and even cure in selected patients by a combination of chemotherapy and surgery. Treatment decisions must be based on the available evidence, which has been the basis for this consensus conference-based guideline delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations. This ESMO guideline is recommended to be used as the basis for treatment and management decisions.

  • 218. Schoemaker, N E
    et al.
    Kuppens, I E L M
    Moiseyenko, V
    Glimelius, Bengt
    Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. Enheten för onkologi.
    Kjaer, M
    Starkhammer, H
    Richel, D J
    Smaaland, R
    Bertelsen, K
    Poulsen, J P
    Voznyi, E
    Norum, J
    Fennelly, D
    Tveit, K M
    Garin, A
    Gruia, G
    Mourier, A
    Sibaud, D
    Lefebvre, P
    Beijnen, J H
    Schellens, J H M
    ten Bokkel Huinink, W W
    A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.2004In: Br J Cancer, ISSN 0007-0920, Vol. 91, no 8, p. 1434-41Article in journal (Other scientific)
  • 219. Schöllkopf, Claudia
    et al.
    Smedby, Karin Ekström
    Hjalgrim, Henrik
    Rostgaard, Klaus
    Gadeberg, Ole
    Roos, Göran
    Porwit-Macdonald, Anna
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
    Adami, Hans-Olov
    Melbye, Mads
    Cigarette smoking and risk of non-Hodgkin's lymphoma: a population-based case-control study2005In: Cancer Epidemiology, Biomarkers and Prevention, ISSN 1055-9965, E-ISSN 1538-7755, Vol. 14, no 7, p. 1791-1796Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Epidemiologic evidence of an association between tobacco smoking and non-Hodgkin's lymphoma has been conflicting. This may reflect that non-Hodgkin's lymphoma comprises several distinct disease entities with different etiologies, as some studies have indicated an association between smoking and follicular lymphoma. OBJECTIVE: To investigate the association between cigarette smoking and non-Hodgkin's lymphoma risk, overall and by subtype. METHODS: As part of a nationwide Danish-Swedish population-based case-control study, we interviewed 3,055 incident non-Hodgkin's lymphoma patients and 3,187 population controls. All lymphomas were uniformly classified according to the WHO classification. We used unconditional logistic regression to estimate adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for the association between cigarette smoking and risk of non-Hodgkin's lymphoma. RESULTS: Cigarette smoking was not associated with the risk of non-Hodgkin's lymphoma overall (OR, 0.97; 95% CI, 0.87-1.08) nor with the major subgroups such as diffuse large B-cell lymphoma (OR, 0.94; 95% CI, 0.79-1.10), chronic lymphocytic leukemia (OR, 0.86; 95% CI, 0.72-1.02), or follicular lymphoma (OR, 1.03; 95% CI, 0.85-1.24). Female smokers were at a marginally increased risk of follicular lymphoma (OR, 1.41; 95% CI, 1.04-1.92). Men who had ever smoked had a significantly increased risk of T-cell lymphoma (OR, 1.67; 95% CI, 1.11-2.51). No dose-response association with cigarette smoking could be established for any lymphoma subgroup. CONCLUSION: We found little evidence of an association between cigarette smoking and non-Hodgkin's lymphoma risk overall. Although increased risks of follicular lymphoma in female smokers and of T-cell lymphoma in male smokers were suggested, no dose-response relationship was observed, leaving limited support for causality.

  • 220.
    Sclafani, F.
    et al.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Brown, G.
    Royal Marsden NHS Fdn Trust, Radiol, Sutton, Surrey, England..
    Cunningham, D.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Wotherspoon, A.
    Royal Marsden NHS Fdn Trust, Histopathol, Sutton, Surrey, England..
    Mendes, L. Sena Teixeira
    Royal Marsden NHS Fdn Trust, Histopathol, Sutton, Surrey, England..
    Evans, J.
    Royal Marsden NHS Fdn Trust, Radiol, Sutton, Surrey, England..
    Peckitt, C.
    Royal Marsden NHS Fdn Trust, Clin Res & Dev, Sutton, Surrey, England..
    Begum, R.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Tait, D.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Capdevila, J.
    Vall dHebron Univ Hosp, Gastrointestinal & Endocrine Tumor Unit, Barcelona, Spain..
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Rosello, S.
    Univ Valencia, Biomed Res Inst INCLIVA, Med Oncol, Valencia, Spain..
    Thomas, J.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Oates, J.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Chau, I.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC)2017In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 28, no S5, article id 504PArticle in journal (Other academic)
  • 221.
    Sclafani, F.
    et al.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Chau, I.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Cunningham, D.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Peckitt, C.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Lampis, A.
    Inst Canc Res, Div Mol Pathol, London, England.;Inst Canc Res, Div Mol Pathol, Sutton, Surrey, England..
    Hahne, J. C.
    Inst Canc Res, Div Mol Pathol, London, England.;Inst Canc Res, Div Mol Pathol, Sutton, Surrey, England..
    Braconi, C.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England.;Inst Canc Res, Div Canc Therapeut, London, England.;Inst Canc Res, Div Canc Therapeut, Sutton, Surrey, England..
    Tabernero, J.
    Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Med Oncol, E-08193 Barcelona, Spain..
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Cervantes, A.
    Univ Valencia, Biomed Res Inst INCLIVA, Dept Hematol & Med Oncol, Valencia, Spain..
    Begum, R.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    De Castro, D. Gonzalez
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Wilson, S. Hulkki
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Eltahir, Z.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Wotherspoon, A.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Tait, D.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Brown, G.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Oates, J.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Valeri, N.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England.;Inst Canc Res, Div Mol Pathol, London, England.;Inst Canc Res, Div Mol Pathol, Sutton, Surrey, England..
    Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial2015In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 26, no 9, p. 1936-1941Article in journal (Refereed)
    Abstract [en]

    Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. We analysed rs61764370 in EXPERT-C, a randomised phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX plus or minus cetuximab in locally advanced rectal cancer. DNA was isolated from formalin-fixed paraffin-embedded tumour tissue and genotyped using a PCR-based commercially available assay. Kaplan-Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment arms. A total of 155/164 (94.5%) patients were successfully analysed, of whom 123 (79.4%) and 32 (20.6%) had the LCS-6 TT and LCS-6 TG genotype, respectively. Carriers of the G allele were found to have a statistically significantly higher rate of complete response (CR) after neoadjuvant therapy (28.1% versus 10.6%; P = 0.020) and a trend for better 5-year progression-free survival (PFS) [77.4% versus 64.5%: hazard ratio (HR) 0.56; P = 0.152] and overall survival (OS) rates (80.3% versus 71.9%: HR 0.59; P = 0.234). Both CR and survival outcomes were independent of the use of cetuximab. The negative prognostic effect associated with KRAS mutation appeared to be stronger in patients with the LCS-6 TT genotype (HR PFS 1.70, P = 0.078; HR OS 1.79, P = 0.082) compared with those with the LCS-6 TG genotype (HR PFS 1.33, P = 0.713; HR OS 1.01, P = 0.995). This analysis suggests that rs61764370 may be a biomarker of response to neoadjuvant treatment and an indicator of favourable outcome in locally advanced rectal cancer possibly by mitigating the poor prognosis of KRAS mutation. In this setting, however, this polymorphism does not appear to predict cetuximab benefit.

  • 222.
    Sclafani, F.
    et al.
    Royal Marsden NHS Fdn Trust, Med, London, England.;Royal Marsden NHS Fdn Trust, Med, Surrey, England..
    Chau, I.
    Royal Marsden NHS Fdn Trust, Med, London, England.;Royal Marsden NHS Fdn Trust, Med, Surrey, England..
    Cunningham, D.
    Royal Marsden NHS Fdn Trust, Med, London, England.;Royal Marsden NHS Fdn Trust, Med, Surrey, England..
    Peckitt, C.
    Royal Marsden NHS Fdn Trust, Res & Dev, London, England.;Royal Marsden NHS Fdn Trust, Res & Dev, Surrey, England..
    Lampis, A.
    Inst Canc Res, Mol Pathol, London SW3 6JB, England.;Inst Canc Res, Mol Pathol, Surrey, England..
    Hahne, J. C.
    Inst Canc Res, Mol Pathol, London SW3 6JB, England.;Inst Canc Res, Mol Pathol, Surrey, England..
    Braconi, C.
    Inst Canc Res, Canc Therapeut, London SW3 6JB, England.;Inst Canc Res, Canc Therapeut, Surrey, England..
    Tabernero, J.
    Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Med Oncol, E-08193 Barcelona, Spain..
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Cervantes, A.
    Univ Valencia, Biomed Res Inst INCLIVA, Hematol & Med Oncol, Valencia, Spain..
    Begum, R.
    Royal Marsden NHS Fdn Trust, Med, London, England.;Royal Marsden NHS Fdn Trust, Med, Surrey, England..
    De Castro, D. Gonzalez
    Royal Marsden NHS Fdn Trust, Mol Diagnost, London, England.;Royal Marsden NHS Fdn Trust, Mol Diagnost, Surrey, England..
    Wilson, S. Hulkki
    Royal Marsden NHS Fdn Trust, Mol Diagnost, London, England.;Royal Marsden NHS Fdn Trust, Mol Diagnost, Surrey, England..
    Eltahir, Z.
    Royal Marsden NHS Fdn Trust, Histopathol, London, England.;Royal Marsden NHS Fdn Trust, Histopathol, Surrey, England..
    Wotherspoon, A.
    Royal Marsden NHS Fdn Trust, Histopathol, London, England.;Royal Marsden NHS Fdn Trust, Histopathol, Surrey, England..
    Tait, D.
    Royal Marsden NHS Fdn Trust, Radiotherapy, London, England.;Royal Marsden NHS Fdn Trust, Radiotherapy, Surrey, England..
    Brown, G.
    Royal Marsden NHS Fdn Trust, Radiol, London, England.;Royal Marsden NHS Fdn Trust, Radiol, Surrey, England..
    Oates, J.
    Royal Marsden NHS Fdn Trust, Med, London, England.;Royal Marsden NHS Fdn Trust, Med, Surrey, England..
    Valeri, N.
    Inst Canc Res, Mol Pathol, London SW3 6JB, England.;Inst Canc Res, Mol Pathol, Surrey, England..
    Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial2015In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 51, no S3, p. S396-S396Article in journal (Other academic)
  • 223.
    Sclafani, F.
    et al.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Chau, I.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Cunningham, D.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Vlachogiannis, G.
    Inst Canc Res, Lab Gastrointestinal Canc Biol & Genom, Div Mol Pathol, Sutton, Surrey, England..
    Eltahir, Z.
    Royal Marsden NHS Fdn Trust, Pathol, Sutton, Surrey, England..
    Lampis, A.
    Inst Canc Res, Lab Gastrointestinal Canc Biol & Genom, Div Mol Pathol, Sutton, Surrey, England..
    Braconi, C.
    Inst Canc Res, Signal Transduct & Mol Pharmacol, Sutton, Surrey, England..
    Kalaitzaki, E.
    Royal Marsden NHS Fdn Trust, Res & Dev, Sutton, Surrey, England..
    De Castro, D. Gonzalez
    Royal Marsden NHS Fdn Trust, Mol Diagnost, Sutton, Surrey, England..
    Wotherspoon, A.
    Royal Marsden NHS Fdn Trust, Pathol, Sutton, Surrey, England..
    Capdevila, J.
    Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain..
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Cervantes, A.
    Univ Valencia, Med Oncol, Biomed Res Inst INCLIVA, Valencia, Spain..
    Begum, R.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Lote, H.
    Inst Canc Res, Lab Gastrointestinal Canc Biol & Genom, Div Mol Pathol, Sutton, Surrey, England..
    Mentrasti, G.
    Inst Canc Res, Lab Gastrointestinal Canc Biol & Genom, Div Mol Pathol, Sutton, Surrey, England..
    Hahne, J. C.
    Inst Canc Res, Lab Gastrointestinal Canc Biol & Genom, Div Mol Pathol, Sutton, Surrey, England..
    Tait, D.
    Royal Marsden NHS Fdn Trust, Med, Sutton, Surrey, England..
    Brown, G.
    Royal Marsden NHS Fdn Trust, Radiol, Sutton, Surrey, England..
    Valeri, N.
    Royal Marsden NHS Fdn Trust, Lab Gastrointestinal Canc Biol & Genom, Div Mol Pathol, Inst Canc Res, Sutton, Surrey, England..
    KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial2016In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 27, no Suppl. 6, article id 525PArticle in journal (Refereed)
  • 224. Sclafani, F.
    et al.
    Cunningham, D.
    Tabernero, J.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Cervantes, A.
    Peckitt, C.
    Tait, D.
    Brown, G.
    De Castro, D. Gonzalez
    Chau, I.
    Updated survival analysis of EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab in MRI-defined high risk rectal cancer patients2013In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 49, no Suppl. 2, p. S487-S487Article in journal (Other academic)
  • 225. Sclafani, F.
    et al.
    Gonzalez, D.
    Cunningham, D.
    Wilson, S. Hulkki
    Peckitt, C.
    Giralt, J.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Rosello Keraenen, S.
    Wotherspoon, A.
    Brown, G.
    Tait, D.
    Oates, J.
    Chau, I.
    RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial2014In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 50, no 8, p. 1430-1436Article in journal (Refereed)
    Abstract [en]

    Background: RAS mutations predict resistance to anti-epidermal growthfactor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. We analysed RAS mutations in 30 non-metastatic rectal cancer patients treated with or without cetuximab within the 31 EXPERT-C trial. Methods: Ninety of 149 patients with tumours available for analysis were KRAS/BRAF wild-type, and randomly assigned to capecitabine plus oxaliplatin (CAPOX) followed by chemoradiotherapy, surgery and adjuvant CAPOX or the same regimen plus cetuximab (CAPOX-C). Of these, four had a mutation of NRAS exon 3, and 84 were retrospectively analysed for additional KRAS (exon 4) and NRAS (exons 2/4) mutations by using bi-directional Sanger sequencing. The effect of cetuximab on study end-points in the RAS wild-type population was analysed. Results: Eleven (13%) of 84 patients initially classified as KRAS/BRAF wild-type were found to have a mutation in KRAS exon 4 (11%) or NRAS exons 2/4 (2%). Overall, 78/149 (52%) assessable patients were RAS wild-type (CAPOX, n = 40; CAPOX-C, n = 38). In this population, after a median follow-up of 63.8 months, in line with the initial analysis, the addition of cetuximab was associated with numerically higher, but not statistically significant, rates of complete response (15.8% versus 7.5%, p = 0.31), 5-year progression-free survival (75.5% versus 67.5%, hazard ratio (HR) 0.61, p = 0.25) and 5-year overall survival (83.8% versus 70%, HR 0.54, p = 0.20). Conclusions: RAS mutations beyond KRAS exon 2 and 3 were identified in 17% of locally advanced rectal cancer patients. Given the small sample size, no definitive conclusions on the effect of additional RAS mutations on cetuximab treatment in this setting can be drawn and further investigation of RAS in larger studies is warranted. (C) 2014 Elsevier Ltd. All rights reserved.

  • 226. Sclafani, F.
    et al.
    Roy, A.
    Cunningham, D.
    Wotherspoon, A.
    Peckitt, C.
    Gonzalez de Castro, D.
    Tabernero, J.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Cervantes, A.
    Eltahir, Z.
    Oates, J.
    Chau, I.
    HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab2013In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 24, no 12, p. 3123-3128Article in journal (Refereed)
    Abstract [en]

    HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported. We evaluated the prevalence of HER2 and its impact on the outcome of high-risk rectal cancer patients treated with neoadjuvant CAPOX and CRT +/- cetuximab in the EXPERT-C trial. Eligible patients with available tumour tissue for HER2 analysis were included. HER2 expression was determined by immunohistochemistry (IHC) in pre-treatment biopsies and/or surgical specimens (score 0-3+). Immunostaining was scored according to the consensus panel recommendations on HER2 scoring for gastric cancer. Tumours with equivocal IHC result (2+) were tested for HER2 amplification by D-ISH. Tumours with IHC 3+ or D-ISH ratio >= 2.0 were classified as HER2+. The impact of HER2 on primary and secondary end points of the study was analysed. Of 164 eligible study patients, 104 (63%) biopsy and 114 (69%) surgical specimens were available for analysis. Only 3 of 104 (2.9%) and 3 of 114 (2.6%) were HER2+, respectively. In 77 patients with paired specimens, concordance for HER2 status was found in 74 (96%). Overall, 141 patients were assessable for HER2 and 6 out of 141 (4.3%) had HER2 overexpression and/or amplification. The median follow-up was 58.6 months. HER2 was not associated with a difference in the outcome for any of the study end points, including in the subset of 90 KRAS/BRAF wild-type patients treated +/- cetuximab. Based on the low prevalence of expression as recorded in the EXPERT-C trial, HER2 does not appear to represent a useful therapeutic target in high-risk rectal cancer. However, the role of HER2 as a potential predictive biomarker of resistance to anti-EGFR-based treatments and a therapeutic target in anti-EGFR refractory metastatic colorectal cancer (CRC) warrants further investigation. Trial registration: ISRCTN Register: 99828560.

  • 227.
    Sclafani, Francesco
    et al.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Brown, Gina
    Royal Marsden NHS Fdn Trust, Dept Radiol, London, England.;Royal Marsden NHS Fdn Trust, Dept Radiol, Surrey, England..
    Cunningham, David
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Wotherspoon, Andrew
    Royal Marsden NHS Fdn Trust, Dept Histopathol, London, England.;Royal Marsden NHS Fdn Trust, Dept Histopathol, Surrey, England..
    Mendes, Larissa Sena Teixeira
    Royal Marsden NHS Fdn Trust, Dept Histopathol, London, England.;Royal Marsden NHS Fdn Trust, Dept Histopathol, Surrey, England..
    Balyasnikova, Svetlana
    Royal Marsden NHS Fdn Trust, Dept Radiol, London, England.;Royal Marsden NHS Fdn Trust, Dept Radiol, Surrey, England..
    Evans, Jessica
    Royal Marsden NHS Fdn Trust, Dept Radiol, London, England.;Royal Marsden NHS Fdn Trust, Dept Radiol, Surrey, England..
    Peckitt, Clare
    Royal Marsden NHS Fdn Trust, Clin Res & Dev, London, England.;Royal Marsden NHS Fdn Trust, Clin Res & Dev, Surrey, England..
    Begum, Ruwaida
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Tait, Diana
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Tabernero, Josep
    Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain..
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Rosello, Susana
    Univ Valencia, Biomed Res Inst INCLIVA, Dept Haematol & Med Oncol, Valencia, Spain..
    Thomas, Janet
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Oates, Jacqui
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Chau, Ian
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
    Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer2017In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 117, no 10, p. 1478-1485Article in journal (Refereed)
    Abstract [en]

    Background: Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. Methods: mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). The agreement between radiologist and pathologist was assessed with the weighted k test while the Kaplan-Meier method was used to estimate survival outcomes. Results: One hundred ninety-one patients were included. Median time from completion of neoadjuvant treatment to pre-operative MRI and surgery was 4.1 weeks (interquartile range (IQR): 3.7-4.7) and 6.6 weeks (IQR: 5.9-7.6), respectively. Fair agreement was found between mrTRG and pTRG when regression was classified according to standard five-tier systems (kappa = 0.24) or modified three-tier systems (kappa = 0.25). Sensitivity and specificity of mrTRG 1-2 (complete/good radiological regression) for the prediction of pathological complete response was 74.4% (95% CI: 58.8-86.5) and 62.8% (95% CI: 54.5-70.6), respectively. Survival outcomes of patients with intermediate pathological regression (pTRG 2) were numerically better if complete/good regression was also observed on imaging (mrTRG 1-2) compared to poor regression (mrTRG 3-5) (5-year recurrence-free survival 76.9% vs 65.9%, P = 0.18; 5-year overall survival 80.6% vs 68.8%, P = 0.22). Conclusions: The agreement between mrTRG and pTRG is low and mrTRG cannot be used as a surrogate of pTRG. Further studies are warranted to assess the ability of mrTRG to identify pathological complete responders for the adoption of non-operative management strategies and to provide complementary prognostic information to pTRG for better risk-stratification after surgery.

  • 228.
    Sclafani, Francesco
    et al.
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Chau, Ian
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Cunningham, David
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Hahne, Jens C.
    Inst Canc Res, London, England.;Inst Canc Res, Surrey, England..
    Vlachogiannis, George
    Inst Canc Res, London, England.;Inst Canc Res, Surrey, England..
    Eltahir, Zakaria
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Lampis, Andrea
    Inst Canc Res, London, England.;Inst Canc Res, Surrey, England..
    Braconi, Chiara
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.;Inst Canc Res, London, England.;Inst Canc Res, Surrey, England..
    Kalaitzaki, Eleftheria
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    De Castro, David Gonzalez
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Wotherspoon, Andrew
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Capdevila, Jaume
    Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, Spain..
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Tarazona, Noelia
    Univ Valencia, Biomed Res Inst INCLIVA, Valencia, Spain..
    Begum, Ruwaida
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Lote, Hazel
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.;Inst Canc Res, London, England.;Inst Canc Res, Surrey, England..
    Wilson, Sanna Hulkki
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Mentrasti, Giulia
    Inst Canc Res, London, England.;Inst Canc Res, Surrey, England..
    Brown, Gina
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Tait, Diana
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Oates, Jacqueline
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England..
    Valeri, Nicola
    Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.;Inst Canc Res, London, England.;Inst Canc Res, Surrey, England..
    KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer2018In: Scientific Reports, ISSN 2045-2322, E-ISSN 2045-2322, Vol. 8, article id 1445Article in journal (Refereed)
    Abstract [en]

    There are limited data on circulating, cell-free, tumour (ct) DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd) PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX +/- cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 cases ctDNA analysis revealed KRAS mutations that were not previously found in tissue. Twenty-two of these (84.6%) were detected following repeat tissue testing by ddPCR. Overall, the ctDNA detection rate in the KRAS mutant population was 66%. Detection of KRAS mutation in ctDNA failed to predict prognosis or refine patient selection for cetuximab. While this study confirms the feasibility of ctDNA analysis in LARC and the high sensitivity of ddPCR, larger series are needed to better address the role of ctDNA as a prognostic or predictive tool in this setting.

  • 229. Sclafani, Francesco
    et al.
    Chau, Ian
    Cunningham, David
    Lampis, Andrea
    Hahne, Jens
    Braconi, Chiara
    Peckitt, Clare
    Gonzalez, David
    Wilson, Sanna Hullki
    Capdevila, Jaume
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Cervantes, Andres
    Begum, Ruwaida
    Brown, Gina
    Tait, Diana M.
    Wotherspoon, Andrew
    Eltahir, Zakaria
    Yusuf-Adam, Sandra
    Oates, Jacqueline Rose
    Valeri, Nicola
    Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.2015In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 33, no 3, article id 581Article in journal (Other academic)
  • 230. Sclafani, Francesco
    et al.
    de Castro, David Gonzalez
    Cunningham, David
    Wilson, Sanna Hulkki
    Peckitt, Clare
    Capdevila, Jaume
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Keraenen, Susana Rosello
    Wotherspoon, Andrew
    Brown, Gina
    Tait, Diana
    Begum, Ruwaida
    Thomas, Janet
    Oates, Jacqueline
    Chau, Ian
    Fc gamma RIIa and Fc gamma RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease2014In: Clinical Cancer Research, ISSN 1078-0432, E-ISSN 1557-3265, Vol. 20, no 17, p. 4511-4519Article in journal (Refereed)
    Abstract [en]

    Purpose: Fc gamma R polymorphisms have been reported to enhance the immune-mediated effects of cetuximab in metastatic colorectal cancer. There are no data on the relationship between these polymorphisms and cetuximab in the early-stage setting. We performed a pharmacogenomic analysis of EXPERT-C, a randomized phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery, and adjuvant CAPOX +/- cetuximab in high-risk, locally advanced rectal cancer. Experimental Design: Fc gamma RIIa-H131R and Fc gamma RIIIa-V158F polymorphisms were analyzed on DNA from peripheral blood samples. Kaplan-Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment arms. Results: Genotyping was successfully performed in 105 of 164 (64%) patients (CAPOX = 54, CAPOX-C = 51). No deviation fromthe Hardy-Weinberg equilibrium or association of these polymorphisms with tumor RAS status was observed. Fc gamma RIIa-131R (HR, 0.38; P = 0.058) and Fc gamma RIIIa-158F alleles (HR, 0.21; P = 0.007) predicted improved progression-free survival (PFS) in patients treated with cetuximab. In the CAPOX-C arm, carriers of both 131R and 158F alleles had a statistically significant improvement in PFS (5 years: 78.4%; HR, 0.22; P = 0.002) and overall survival (OS; 5 years: 86.4%; HR, 0.24; P = 0.018) when compared with patients homozygous for 131H and/or 158V (5-year PFS: 35.7%; 5-year OS: 57.1%). An interaction between cetuximab benefit and 131R and 158F alleles was found for PFS (P = 0.017) and remained significant after adjusting for prognostic variables (P = 0.003). Conclusion: This is the first study investigating Fc gamma RIIa and Fc gamma RIIIa polymorphisms in patients with early-stage colorectal cancer treated with cetuximab. We showed an increased clinical benefit from cetuximab in the presence of 131R and 158F alleles.

  • 231. Sclafani, Francesco
    et al.
    Gonzalez, David
    Cunningham, David
    Wilson, Sanna Hulkki
    Peckitt, Clare
    Tabernero, Josep
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Cervantes, Andres
    Dewdney, Alice
    Wotherspoon, Andrew
    Brown, Gina
    Tait, Diana
    Oates, Jacqueline
    Chau, Ian
    TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial2014In: Journal of the National Cancer Institute, ISSN 0027-8874, E-ISSN 1460-2105, Vol. 106, no 7, p. dju121-Article in journal (Refereed)
    Abstract [en]

    In this updated analysis of the EXPERT-C trial we show that, in magnetic resonance imaging-defined, high-risk, locally advanced rectal cancer, adding cetuximab to a treatment strategy with neoadjuvant CAPOX followed by chemoradiotherapy, surgery, and adjuvant CAPOX is not associated with a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in both KRAS/BRAF wild-type and unselected patients. In a retrospective biomarker analysis, TP53 was not prognostic but emerged as an independent predictive biomarker for cetuximab benefit. After a median follow-up of 65.0 months, TP53 wild-type patients (n = 69) who received cetuximab had a statistically significant better PFS (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and OS (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) than TP53 wild-type patients who were treated in the control arm. An interaction between TP53 status and cetuximab effect was found (P < .05) and remained statistically significant after adjusting for statistically significant prognostic factors and KRAS.

  • 232. Sclafani, Francesco
    et al.
    Gonzalez, David
    Cunningham, David
    Wilson, Sanna Hullki
    Peckitt, Clare
    Tabernero, Josep
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Cervantes, Andres
    Wotherspoon, Andrew
    Brown, Gina
    Tait, Diana M.
    Oates, Jacqueline Rose
    Chau, Ian
    RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).2014In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 3Article in journal (Other academic)
  • 233. Sclafani, Francesco
    et al.
    Gonzalez, David
    Cunningham, David
    Wilson, Sanna Hullki
    Peckitt, Clare
    Tabernero, Josep
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Cervantes, Andres
    Wotherspoon, Andrew
    Dewdney, Alice
    Brown, Gina
    Tait, Diana M.
    Oates, Jacqueline Rose
    Chau, Ian
    Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial2014In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 3Article in journal (Other academic)
  • 234. Sclafani, Francesco
    et al.
    Gonzalez de Castro, David
    Cunningham, David
    Wilson, Sanna Hulkki
    Peckitt, Clare
    Capdevila, Jaume
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Keranen, Susana Rosello
    Begum, Ruwaida
    Brown, Gina
    Tait, Diana M.
    Wotherspoon, Andrew
    Thomas, Janet
    Oates, Jacqueline Rose
    Chau, Lan
    FC gamma RIIa and FC gamma RIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial2014In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 15Article in journal (Refereed)
  • 235. Sclafani, Francesco
    et al.
    Peckitt, Clare
    Cunningham, David
    Evans, Jessica
    Brown, Gina
    Tabernero, Josep
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Cervantes, Andres
    Tait, Diana M.
    Wotherspoon, Andrew
    Thomas, Janet
    Oates, Jacqueline Rose
    Chau, Ian
    Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC)2014In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 15Article in journal (Refereed)
  • 236.
    Sclafani, Francesco
    et al.
    Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England..
    Peckitt, Clare
    Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England..
    Cunningham, David
    Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England..
    Tait, Diana
    Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England..
    Giralt, Jordi
    Vall dHebron Univ Hosp, Univ Autonoma Barcelona, Dept Med Oncol, Barcelona, Spain..
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Keranen, Susana Rosello
    Univ Valencia, Biomed Res Inst INCLIVA, Dept Hematol & Med Oncol, E-46003 Valencia, Spain..
    Bateman, Andrew
    Univ Southampton, Southampton Gen Hosp, Canc Sci Unit, Southampton SO9 5NH, Hants, England..
    Hickish, Tamas
    Bournemouth Univ, Poole Hosp NHS Fdn Trust, Dept Med Oncol, Poole BH12 5BB, Dorset, England..
    Tabernero, Josep
    Vall dHebron Univ Hosp, Univ Autonoma Barcelona, Dept Med Oncol, Barcelona, Spain..
    Thomas, Janet
    Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England..
    Brown, Gina
    Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England..
    Oates, Jacqueline
    Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England..
    Chau, Ian
    Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England..
    Short-and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial2015In: International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, E-ISSN 1879-355X, Vol. 93, no 2, p. 303-312Article in journal (Refereed)
    Abstract [en]

    Objective: Intensified preoperative treatments have been increasingly investigated in locally advanced rectal cancer (LARC), but limited data are available for the impact of these regimens on quality of life (QoL) and bowel function (BF). We assessed these outcome measures in EXPERT-C, a randomized phase 2 trial of neoadjuvant capecitabine combined with oxaliplatin (CAPOX), followed by chemoradiation therapy (CRT), total mesorectal excision, and adjuvant CAPOX with or without cetuximab in magnetic resonance imaging-defined, high-risk LARC. Methods and Materials: QoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR29 questionnaires. Bowel incontinence was assessed using the modified Fecal Incontinence Severity Index questionnaire. Results: Compared to baseline, QoL scores during preoperative treatment were better for symptoms associated with the primary tumor in the rectum (blood and mucus in stool, constipation, diarrhea, stool frequency, buttock pain) but worse for global health status, role functioning, and symptoms related to the specific safety profile of each treatment modality. During follow-up, improved emotional functioning and lessened anxiety and insomnia were observed, but deterioration of body image, increased urinary incontinence, less sexual interest (men), and increased impotence and dyspareunia were observed. Cetuximab was associated with a deterioration of global health status during neoadjuvant chemotherapy but did not have any long-term detrimental effect. An improvement in bowel continence was observed after preoperative treatment and 3 years after sphincter-sparing surgery. Conclusions: Intensifying neoadjuvant treatment by administering induction systemic chemotherapy before chemoradiation therapy improves tumor-related symptoms and does not appear to have a significantly detrimental effect on QoL and BF, in both the short and the long term.

  • 237.
    Sclafani, Francesco
    et al.
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.
    Wilson, Sanna Hulkki
    Royal Marsden NHS Fdn Trust, Ctr Mol Pathol, Dept Mol Diagnost, London, England.
    Cunningham, David
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.
    De Castro, David Gonzalez
    Royal Marsden NHS Fdn Trust, Ctr Mol Pathol, Dept Mol Diagnost, London, England.
    Kalaitzaki, Eleftheria
    Royal Marsden NHS Fdn Trust, Dept Clin Res & Dev, London, England.
    Begum, Ruwaida
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.
    Wotherspoon, Andrew
    Royal Marsden NHS Fdn Trust, Dept Histopathol, London, England.
    Capdevila, Jaume
    Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Rosello, Susana
    Univ Valencia, Biomed Res Inst INCLIVA, Dept Haematol & Med Oncol, Valencia, Spain.
    Thomas, Janet
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.
    Tait, Daina
    Royal Marsden NHS Fdn Trust, Dept Radiotherapy, London, England.
    Brown, Gina
    Royal Marsden NHS Fdn Trust, Dept Radiol, London, England.
    Oates, Jacqui
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.
    Chau, Ian
    Royal Marsden NHS Fdn Trust, Dept Med, London, England.
    Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients2020In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 146, no 1, p. 94-102Article in journal (Refereed)
    Abstract [en]

    Little information is available on the clinical significance of cancer-related genes such as KRAS, NRAS, BRAF, PIK3CA and TP53 in nonmetastatic rectal cancer. We investigated mutations of these genes in a large prospective series of locally advanced rectal cancer (LARC) patients who were recruited into two phase II trials. Mutational analyses were performed with diagnostically validated methods including polymerase chain reaction, capillary electrophoresis single-strand conformational analysis, Sanger sequencing and next-generation sequencing. Associations between single or multiple gene mutations and clinicopathological characteristics and treatment outcomes were explored. Of these 269, 210 (78%) patients were assessable. Mutations of KRAS, NRAS, BRAF, PIK3CA and TP53 occurred in 43, 9, 4, 9 and 60% of patients, respectively. Concordance between paired biopsy and resection specimens was 82% for KRAS, 95% for NRAS, 99% for BRAF, 96% for PIK3CA and 63% for TP53. TP53 mutations were associated with extramural venous invasion on baseline MRI (78% vs. 65%, p = 0.04), poor pathological tumour regression (23% vs. 36%, p = 0.05) and a trend toward a worse 5-year progression-free survival (PFS; 60% vs. 74%, HR 1.59, p = 0.06). Patients with tumours harbouring mutation of TP53 and either KRAS or NRAS (32%) had a worse 5-year PFS than those with TP53/KRAS/NRAS wild-type tumours (54% vs. 72%, HR 1.75, p = 0.02). In univariate analysis, BRAF mutation predicted poor 5-year overall survival only among patients treated without cetuximab (20% vs. 73%, HR 3.29, p = 0.03). This is one of the largest biomarker studies in a prospective, largely homogeneous, LARC population. Our findings are hypothesis generating and require validation in independent series.

  • 238.
    Siesing, Christina
    et al.
    Lund Univ, Skane Univ Hosp, Div Oncol & Pathol, Dept Clin Sci, Lund, Sweden..
    Sorbye, Halfdan
    Univ Bergen, Haukeland Univ Hosp, Dept Oncol, Bergen, Norway.;Univ Bergen, Dept Clin Sci, Bergen, Norway..
    Dragomir, Anca
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical and experimental pathology. Uppsala Univ, Uppsala Univ Hosp, Sect Pathol, Uppsala, Sweden.
    Pfeiffer, Per
    Odense Univ Hosp, Dept Oncol, Odense, Denmark..
    Qvortrup, Camilla
    Odense Univ Hosp, Dept Oncol, Odense, Denmark..
    Ponten, Fredrik
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical and experimental pathology. Uppsala Univ, Uppsala Univ Hosp, Sect Pathol, Uppsala, Sweden.
    Jirström, Karin
    Lund Univ, Skane Univ Hosp, Div Oncol & Pathol, Dept Clin Sci, Lund, Sweden..
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Eberhard, Jakob
    Lund Univ, Skane Univ Hosp, Div Oncol & Pathol, Dept Clin Sci, Lund, Sweden..
    High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer2017In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 12, no 8, article id e0182512Article in journal (Refereed)
    Abstract [en]

    Background: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinumbased chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy.

    Methods: Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan- Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progressionfree survival (PFS).

    Results: High RBM3 expression, both nuclear and cytoplasmic, was an independent prognostic factor for prolonged OS (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.50-0.90 and HR 0.66, 95% CI 0.48-0.91, respectively). PFS was significantly longer in patients with high RBM3 expression who had received first-line oxaliplatin based treatment, compared to those who had received irinotecan based treatment, both regarding nuclear and cytoplasmic expression (p-value 0.020 and 0.022 respectively).

    Conclusion: High RBM3 expression is an independent predictor of prolonged survival in mCRC patients, in particular in patients treated with first-line oxaliplatin based chemotherapy.

  • 239. Simard, Julia F
    et al.
    Baecklund, Fredrik
    Chang, Ellen T
    Baecklund, Eva
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Rheumatology.
    Hjalgrim, Henrik
    Adami, Hans-Olov
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Smedby, Karin E
    Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes2013In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 132, no 11, p. 2659-2666Article in journal (Refereed)
    Abstract [en]

    Lifestyle factors and medical history are known to influence risk of non-Hodgkin lymphoma (NHL). Whether these factors affect the prognosis of NHL, especially its subtypes, is unclear. To investigate this, the association between these factors and all-cause and lymphoma-related mortality was assessed in a population-based cohort of 1,523 Swedish NHL patients included in the Scandinavian Lymphoma Etiology study in 1999-2002. Participants contributed time from NHL diagnosis until death or October 1, 2010, with virtually complete follow-up through linkage to the Swedish Cause of Death Register. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using stratified and multivariable-adjusted Cox regression models. During a median follow-up of 8.8 years, 670 patients (44%) died, with the majority of deaths attributed to lymphoma (86%). Current versus never smoking at diagnosis was associated with increased rate of all-cause death for all NHL (HR = 1.5, 1.2-1.8) and diffuse large B-cell lymphoma (HR = 1.8, 1.2-2.7). Low educational level (HR = 1.3, 1.1-1.7, <9 vs. >12 years) and NHL risk-associated autoimmune disease (HR = 1.4, 1.0-1.8) were associated with death for all NHL combined. However, evidence of an association with lymphoma-related death was limited. Body mass index, recent sunbathing and family history of hematopoietic malignancy were not consistently associated with death after NHL or its specific subtypes. These results add to the evidence that cigarette smoking, socioeconomic status and certain autoimmune diseases affect survival after NHL. Further investigations are needed to determine how these factors should be incorporated into clinical prognostic assessment.

  • 240. Sjövall, A.
    et al.
    Holm, T.
    Singnomklao, T.
    Granath, F.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. Enheten för onkologi.
    Cedermark, B.
    Colon cancer management and outcome in relation to individual hospitals in a defined population2007In: British Journal of Surgery, ISSN 0007-1323, E-ISSN 1365-2168, Vol. 94, no 4, p. 491-499Article in journal (Refereed)
    Abstract [en]

    Background:The Stockholm and Gotland region in Sweden has a common management protocol for the treatment of colon cancer. The aim of this study was to assess the management and treatment of colon cancer in the region and to try to identify ways to improve the outcome further.Methods:Clinical data on all patients diagnosed with colon cancer in the region's nine hospitals between January 1996 and December 2000 were prospectively collected. Patients were followed until December 2004, and their management and outcome analysed.Results:Colon cancer was diagnosed in 2775 patients. An elective operation was performed in 2116 (76·3 per cent) patients and an emergency procedure in 590 (21·3 per cent). Emergency surgery was an independent risk factor for death. The crude overall cumulative 5-year survival was 46·2 per cent. A multivariable analysis of risk of dying and risk of local recurrence showed significant differences between hospitals. The number of lymph nodes examined in the specimens also differed between hospitals.Conclusion:Differences in the management and outcome of colon cancer in the nine hospitals, despite a common management protocol, indicate a need for improving collaboration between hospitals and multidisciplinary management.

  • 241. Sjövall, A
    et al.
    Järv, V
    Blomqvist, L
    Singnomklao, T
    Cedermark, B
    Glimelius, Bengt
    Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. Enh för onkologi.
    Holm, T
    The potential for improved outcome in patients with hepatic metastases from colon cancer: a population-based study.2004In: Eur J Surg Oncol, ISSN 0748-7983, Vol. 30, no 8, p. 834-41Article in journal (Other scientific)
  • 242. Sjövall, Annika
    et al.
    Granath, Fredrik
    Cedermark, Björn
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
    Holm, Torbjörn
    Loco-regional Recurrence from Colon Cancer: A Population-based Study2007In: Annals of Surgical Oncology, ISSN 1068-9265, E-ISSN 1534-4681, Vol. 14, no 2, p. 432-440Article in journal (Refereed)
    Abstract [en]

    Background  The survival after colon cancer surgery has not improved to the same extent as after rectal cancer treatment and studies on loco-regional recurrence after colon cancer surgery are scarce. The aim of this study was to assess the problem of loco-regional recurrence after potentially curative resections for colon cancer, regarding incidence, risk factors, management, and outcome. Methods  All 1,856 patients submitted to potentially curative surgery for colon cancer in the Stockholm/Gotland region in Sweden between 1996 and 2000 were followed until January 2005 or until death. Follow-up data were prospectively collected. Risk factors for loco-regional recurrences were analyzed, treatment and outcome for patients with recurrence was studied. Results  The cumulative 5-year incidence of loco-regional recurrence was 11.5%. Tumor locations in the right flexure and in the sigmoid colon, bowel perforation and emergent surgery were identified as independent risk factors for loco-regional recurrence. The risk also increased with increasing T- and N-stage. The median survival for all 192 patients with loco-regional recurrence was 9 months. Surgery was performed in 110 (57%) patients. In 23 (12%) patients a complete tumor clearance was achieved and the estimated 5-year survival in this group was 43%. Conclusion  Loco-regional recurrence from colon cancer is a significant clinical problem. A multidisciplinary treatment approach, including preoperative staging, a complete resection of the recurrence and more effective adjuvant treatments may improve the outcome.

  • 243. Skibola, Christine F.
    et al.
    Berndt, Sonja I.
    Vijai, Joseph
    Conde, Lucia
    Wang, Zhaoming
    Yeager, Meredith
    de Bakker, Paul I. W.
    Birmann, Brenda M.
    Vajdic, Claire M.
    Foo, Jia-Nee
    Bracci, Paige M.
    Vermeulen, Roel C. H.
    Slager, Susan L.
    de Sanjose, Silvia
    Wang, Sophia S.
    Linet, Martha S.
    Salles, Gilles
    Lan, Qing
    Severi, Gianluca
    Hjalgrim, Henrik
    Lightfoot, Tracy
    Melbye, Mads
    Gu, Jian
    Ghesquieres, Herve
    Link, Brian K.
    Morton, Lindsay M.
    Holly, Elizabeth A.
    Smith, Alex
    Tinker, Lesley F.
    Teras, Lauren R.
    Kricker, Anne
    Becker, Nikolaus
    Purdue, Mark P.
    Spinelli, John J.
    Zhang, Yawei
    Giles, Graham G.
    Vineis, Paolo
    Monnereau, Alain
    Bertrand, Kimberly A.
    Albanes, Demetrius
    Zeleniuch-Jacquotte, Anne
    Gabbas, Attilio
    Chung, Charles C.
    Burdett, Laurie
    Hutchinson, Amy
    Lawrence, Charles
    Montalvan, Rebecca
    Liang, Liming
    Huang, Jinyan
    Ma, Baoshan
    Liu, Jianjun
    Adami, Hans-Olov
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Ye, Yuanqing
    Nowakowski, Grzegorz S.
    Dogan, Ahmet
    Thompson, Carrie A.
    Habermann, Thomas M.
    Novak, Anne J.
    Liebow, Mark
    Witzig, Thomas E.
    Weiner, George J.
    Schenk, Maryjean
    Hartge, Patricia
    De Roos, Anneclaire J.
    Cozen, Wendy
    Zhi, Degui
    Akers, Nicholas K.
    Riby, Jacques
    Smith, Martyn T.
    Lacher, Mortimer
    Villano, Danylo J.
    Maria, Ann
    Roman, Eve
    Kane, Eleanor
    Jackson, Rebecca D.
    North, Kari E.
    Diver, W. Ryan
    Turner, Jenny
    Armstrong, Bruce K.
    Benavente, Yolanda
    Boffetta, Paolo
    Brennan, Paul
    Foretova, Lenka
    Maynadie, Marc
    Staines, Anthony
    McKay, James
    Brooks-Wilson, Angela R.
    Zheng, Tongzhang
    Holford, Theodore R.
    Chamosa, Saioa
    Kaaks, Rudolph
    Kelly, Rachel S.
    Ohlsson, Bodil
    Travis, Ruth C.
    Weiderpass, Elisabete
    Clave, Jacqueline
    Giovannucci, Edward
    Kraft, Peter
    Virtamo, Jarmo
    Mazza, Patrizio
    Cocco, Pierluigi
    Ennas, Maria Grazia
    Chiu, Brian C. H.
    Fraumeni, Joseph R., Jr.
    Nieters, Alexandra
    Offit, Kenneth
    Wu, Xifeng
    Cerhan, James R.
    Smedby, Karin E.
    Chanock, Stephen J.
    Rothman, Nathaniel
    Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region2014In: American Journal of Human Genetics, ISSN 0002-9297, E-ISSN 1537-6605, Vol. 95, no 4, p. 462-471Article in journal (Refereed)
    Abstract [en]

    Genome-wide association studies (GWASs) of follicular lymphoma (FL) have previously identified human leukocyte antigen (HLA) gene variants. To identify additional FL susceptibility loci, we conducted a large-scale two-stage GWAS in 4,523 case subjects and 13,344 control subjects of European ancestry. Five non-HLA loci were associated with FL risk: 11q23.3 (rs4938573, p = 5.79 x 10(-20)) near CXCR5; 11q24.3 (rs4937362, p = 6.76 x 10(-11)) near ETS1; 3q28 (rs6444305, p = 1.10 x 10(-10)) in LPP; 18q21.33 (rs17749561, p = 8.28 x 10(-10)) near BCL2; and 8q24.21 (rs13254990, p = 1.06 x 10(-8)) near PVT1. In an analysis of the HLA region, we identified four linked HLA-DR beta 1 multiallelic amino acids at positions 11, 13, 28, and 30 that were associated with FL risk (P-omnibus = 4.20 x 10(-67) to 2.67 x 10(-70)). Additional independent signals included rs17203612 in HLA class II (odds ratio [ORper-allele] = 1.44; p = 4.59 x 10(-16)) and rs3130437 in HLA class I (ORper-allele = 1.23; p = 8.23 x 10(-9)). Our findings further expand the number of loci associated with FL and provide evidence that multiple common variants outside the HLA region make a significant contribution to FL risk.

  • 244. Smedby, K E
    et al.
    Akerman, M
    Hildebrand, H
    Glimelius, B
    Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology. Onkologi.
    Ekbom, A
    Askling, J
    Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma.2005In: Gut, ISSN 0017-5749, Vol. 54, no 1, p. 54-9Article in journal (Other scientific)
  • 245. Smedby, Karin Ekström
    et al.
    Hjalgrim, Henrik
    Askling, Johan
    Chang, Ellen T.
    Gregersen, Henrik
    Porwit-MacDonald, Anna
    Sundström, Christer
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Genetics and Pathology.
    Åkerman, Måns
    Melbye, Mads
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
    Adami, Hans-Olov
    Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype2006In: Journal of the National Cancer Institute, ISSN 0027-8874, E-ISSN 1460-2105, Vol. 98, no 1, p. 51-60Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Some autoimmune and chronic inflammatory disorders are associated with increased risks of non-Hodgkin lymphoma (NHL). Because different NHL subtypes develop at different stages of lymphocyte differentiation, associations of autoimmune and inflammatory disorders with specific NHL subtypes could lead to a better understanding of lymphomagenic mechanisms. METHODS: In a population-based case-control study in Denmark and Sweden, 3055 NHL patients and 3187 matched control subjects were asked about their history of autoimmune and chronic inflammatory disorders, markers of severity, and treatment. Logistic regression with adjustment for study matching factors was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for NHL overall and for NHL subtypes. RESULTS: Risks of all NHL were increased in association with rheumatoid arthritis (OR = 1.5, 95% CI = 1.1 to 1.9), primary Sjögren syndrome (OR = 6.1, 95% CI = 1.4 to 27), systemic lupus erythematosus (OR = 4.6, 95% CI = 1.0 to 22), and celiac disease (OR = 2.1, 95% CI = 1.0 to 4.8). All of these conditions were also associated with diffuse large B-cell lymphoma, and some were associated with marginal zone, lymphoplasmacytic, or T-cell lymphoma. Ever use of nonsteroidal anti-inflammatory drugs, systemic corticosteroids, and selected immunosuppressants was associated with risk of NHL in rheumatoid arthritis patients but not in subjects without rheumatoid arthritis. Also, multivariable adjustment for treatment had little impact on risk estimates. Psoriasis, sarcoidosis, and inflammatory bowel disorders were not associated with increased risk of NHL overall or of any NHL subtype. CONCLUSIONS: Our results confirm the associations between certain autoimmune disorders and risk of NHL and suggest that the associations may not be general but rather mediated through specific NHL subtypes. These NHL subtypes develop during postantigen exposure stages of lymphocyte differentiation, consistent with a role of antigenic drive in autoimmunity-related lymphomagenesis.

  • 246. Smedby, Karin Ekström
    et al.
    Hjalgrim, Henrik
    Melbye, Mads
    Torrång, Anna
    Rostgaard, Klaus
    Munksgaard, Lars
    Adami, Johanna
    Hansen, Mads
    Porwit-MacDonald, Anna
    Jensen, Bjarne Anker
    Roos, Göran
    Pedersen, Bjarne Bach
    Sundström, Christer
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Genetics and Pathology.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
    Adami, Hans-Olov
    Ultraviolet radiation exposure and risk of malignant lymphomas2005In: Journal of the National Cancer Institute, ISSN 0027-8874, E-ISSN 1460-2105, Vol. 97, no 3, p. 199-209Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: The incidence of malignant lymphomas has been increasing rapidly, but the causes of these malignancies remain poorly understood. One hypothesis holds that exposure to ultraviolet (UV) radiation increases lymphoma risk. We tested this hypothesis in a population-based case-control study in Denmark and Sweden. METHODS: A total of 3740 patients diagnosed between October 1, 1999, and August 30, 2002, with incident malignant lymphomas, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Hodgkin lymphoma, and 3187 population controls provided detailed information on history of UV exposure and skin cancer and information on other possible risk factors for lymphomas. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by logistic regression. Statistical tests were two-sided. RESULTS: Multivariable-adjusted analyses revealed consistent, statistically significant negative associations between various measures of UV light exposure and risk of non-Hodgkin lymphoma. A high frequency of sun bathing and sunburns at age 20 years and 5-10 years before the interview and sun vacations abroad were associated with 30%-40% reduced risks of non-Hodgkin lymphoma (e.g., for sunbathing four times a week or more at age 20 versus never sunbathing, OR = 0.7, 95% CI = 0.6 to 0.9; for two or more sunburns a year at age 20 versus no sunburns, OR = 0.6, 95% CI = 0.5 to 0.8). These inverse associations increased in strength with increasing levels of exposure (all P(trend)< or =.01). Similar, albeit weaker, associations were observed for Hodgkin lymphoma. There were no clear differences among non-Hodgkin lymphoma subtypes, although associations were stronger for B-cell than for T-cell lymphomas. A history of skin cancer was associated with a doubling in risks of both non-Hodgkin and Hodgkin lymphoma. CONCLUSIONS: A history of high UV exposure was associated with reduced risk of non-Hodgkin lymphoma. The positive association between skin cancer and malignant lymphomas is, therefore, unlikely to be mediated by UV exposure.

  • 247. Sorbye, H.
    et al.
    Cvancarova, M.
    Qvortrup, C.
    Pfeiffer, P.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer2013In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 24, no 9, p. 2354-2360Article in journal (Refereed)
    Abstract [en]

    In metastatic colorectal cancer (mCRC) trials, median survival has increased from 6 months to above 20 months during the previous decades. Uncertainty exists in how this survival improvement has translated to the general mCRC population. Survival data from patients with synchronous mCRC were collected from the Norwegian (1980-2008), Swedish (1996-2008) and Danish (2001-09) cancer registries. A total of 29 628 patients were identified. From 1980-1985 to 2006-2008, median survival increased from 5 to 10 months for Norwegian patients. Three-year survival increased from 7% to 21% and 5-year survival from 4% to 9%. For patients < 60 years, median survival was doubled to 16 months, 3-year survival increased fourfold up to 28% and 5-year survival threefold up to 14%. Similar improvements were seen in Sweden and Denmark. In all countries, the improved outcome was seen especially for younger patients and much less for patients > 75 years of age. An increase in median and long-term survival over time was found in unselected population-based registries of patients with synchronous mCRC. The improved outcome in survival was especially seen in younger patients, raising concerns over our ability to adapt available treatment options for elderly patients.

  • 248. Sorbye, Halfdan
    et al.
    Dragomir, Anca
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical and experimental pathology.
    Sundström, Magnus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    Pfeiffer, Per
    Thunberg, Ulf
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical and experimental pathology.
    Bergfors, Monica
    Department of Pathology, Uppsala University Hospital, Uppsala, Sweden.
    Aasebo, Kristine
    Eide, Geir Egil
    Ponten, Fredrik
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical and experimental pathology.
    Qvortrup, Camilla
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
    High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort2015In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 10, no 6, article id e0131046Article in journal (Refereed)
    Abstract [en]

    RAS and BRAF mutations impact treatment and prognosis of metastatic colorectal cancer patients (mCRC), but the knowledge is based on trial patients usually not representative for the general cancer population. Patient characteristics, treatment and efficacy according to KRAS, BRAF and MSI status were analyzed in a prospectively collected unselected population-based cohort of 798 non-resectable mCRC patients. The cohort contained many patients with poor performance status (39% PS 2-4) and elderly (37% age>75), groups usually not included in clinical trials. Patients without available tissue micro array (TMA) (42%) had worse prognostic factors and inferior survival (all patients; 7m vs 11m, chemotherapy-treated; 12m vs 17m). The 92 patients (21%) with BRAF mutation had a poor prognosis regardless of microsatellite instability, but receipt of 1-2nd chemotherapy was similar to wildtype BRAF patients. Median survival in this cohort varied from 1 month in BRAF mutated patients not given chemotherapy to 26 months in wildtype KRAS/BRAF patients <75 years in good PS. TMA availability, BRAF mutation and KRAS mutation were all independent prognostic factors for survival. The observed 21% BRAF mutation incidence is higher than the previously and repeatedly reported incidence of 5-12% in mCRC. Screening for BRAF mutations before selection of treatment is relevant for many patients, especially outside clinical trials. A BRAF mutation only partly explained the very poor prognosis of many mCRC patients. Survival in unselected metastatic colorectal cancer patients is extremely variable and subgroups have an extremely short survival compared to trial patients. Patients without available TMA had worse prognostic factors and shorter survival, which questions the total generalizability of present TMA studies and implies that we lack information on the biologically worst mCRC cases. Lack of available tissue is an important underexposed issue which introduces sample bias, and this should be recognized more clearly when conclusions are made from translational mCRC studies.

  • 249. Sorbye, Halfdan
    et al.
    Mauer, Murielle
    Gruenberger, Thomas
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    Poston, Graeme J.
    Schlag, Peter M.
    Rougier, Philippe
    Bechstein, Wolf O.
    Primrose, John N.
    Walpole, Euan T.
    Finch-Jones, Meg
    Jaeck, Daniel
    Mirza, Darius
    Parks, Rowan W.
    Collette, Laurence
    Van Cutsem, Eric
    Scheithauer, Werner
    Lutz, Manfred P.
    Nordlinger, Bernard
    Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983)2012In: Annals of Surgery, ISSN 0003-4932, E-ISSN 1528-1140, Vol. 255, no 3, p. 534-539Article in journal (Refereed)
    Abstract [en]

    Objective: In EORTC study 40983, perioperative FOLFOX increased progression-free survival (PFS) compared with surgery alone for patients with initially 1 to 4 resectable liver metastases from colorectal cancer (CRC). We conducted an exploratory retrospective analysis to identify baseline factors possibly predictive for a benefit of perioperative FOLFOX on PFS. Methods: The analysis was based on 237 events from 342 eligible patients. Cox proportional hazards regression models with a significance level of 0.1 were used to build up univariate and multivariate models. Results: After adjustment for identified prognostic factors, moderately (5.1-30 ng/mL) and highly (>30 ng/mL) elevated carcinoembryonic antigen (CEA) serum levels were both predictive for the benefit of perioperative chemotherapy (interaction P = 0.07; hazard ratio [HR] = 0.58 and HR = 0.52 for treatment benefit). For patients with moderately or highly elevated CEA (>5 ng/mL), the 3-year PFS was 35% with perioperative chemotherapy compared to 20% with surgery alone. Performance status (PS) 0 and BMI lower than 30 were also predictive for the benefit of perioperative chemotherapy (interaction P = 0.04 and P = 0.02). However, the number of patients with PS 1 and BMI 30 or higher were limited. The benefit of perioperative therapy was not influenced by the number of metastatic lesions (1 vs 2-4, interaction HR = 0.98). Conclusions: Perioperative FOLFOX seems to benefit in particular patients with resectable liver metastases from CRC when CEA is elevated and when PS is unaffected, regardless of the number of metastatic lesions.

  • 250. Steineck, Gunnar
    et al.
    Glimelius, Bengt
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Oncology.
    What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?2013In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 52, no 8, p. 1589-1592Article in journal (Other academic)
23456 201 - 250 of 295
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf